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Osteoarthritis is arguably the most common ailment in both dogs and people in the developed 
World.  Treatment for osteoarthritis is currently symptomatic.  Development of therapies 
designed at stopping the progression of osteoarthritis, require a method of evaluating efficacy.  
Objective analysis by measuring joint metabolism via clinical trials of the cross-over design is 
currently not possible with the methods utilized. 
 
Extracellular matrix degradation is a hallmark of osteoarthritis.  The matrix metalloproteinases 
are major degradative enzymes.  There are currently no commercially available assays to 
measure canine matrix metalloproteinases.  Human and canine matrix metalloproteinases are 
highly homologous.  The use of antibodies and assays designed to detect human matrix 
metalloproteinases may also detect canine molecules. 
 
A commercially available human enzyme-linked immunosorbent assay (ELISA) was tested 
against canine samples without success.   
 
Casein zymography detected the presence of canine enzymes weighing the same as human 
matrix metalloproteinase 3 (MMP-3) and matrix metalloproteinase 13 (MMP-13). Inhibition of 
the casein degradation was achieved by the addition of ethylenediamine tetra-acetic acid 
(EDTA).  The presence of a protein of the correct molecular weight with the ability to digest 
casein that is inhibited by EDTA is only circumstantial and does not definitively identify the 
enzymes. 
 
Enzyme-assisted immunoelectroblotting (Western blotting) utilizing human polyclonal 




CHAPTER 1. INTRODUCTION AND LITERATURE REVIEW 
 
OSTEOARTHRITIS 
   
Importance of Osteoarthritis 
 
Osteoarthritis (OA) is characterized by pathologic change of the synovial joint accompanied by a 
variable degree of pain and resultant disability.  Osteoarthritis has been estimated to affect at 
least 20 percent of the canine population over one year of age.1-5  In the United States, OA 
effects approximately 60 percent of people older than 60 years of age or about 40 million 
people.6, 7  In veterinary and human medicine, OA is the most common form of joint disease.8  It 
is the most common cause of chronic pain and lameness in companion animals affecting 8 
million dogs in the United States.4, 9  Osteoarthritis is not age or breed specific.  However, large 
and giant breed dogs and working dogs are over-represented.10, 11 Euthanasia because of 
appendicular OA is the leading cause of death of military working dogs.12  Arthritis is the most 
frequently reported cause of work-related disability affecting adults in the United States.8 In the 
developed world, OA ranks in the top three health care problems based on dollars spent with an 
estimated 15.5 billion dollars in the United States.13, 14   
 
Current treatments for OA may reduce pain and encourage mobility but do not inhibit the 
cartilage degradation causing the symptoms.15  The treatment of OA is currently palliative.  
Weight reduction decreases the stress placed on abnormal joints.  Daily, low-impact exercise is 
instituted to retain muscle mass.  Pain is controlled with non-steroidal anti-inflammatory drugs or 
opioids.  The use of disease modifying drugs and chondroprotectants are advocated to slow the 
progress of OA.16-19  However, their efficacy is questionable.20 
 
Osteoarthritis is a complex condition with a multitude of interacting biomechanical and 
biochemical factors.  It is characterized by deterioration of articular cartilage; osteophyte 
formation and bone remodeling; proliferation of periarticular tissues; and a low-grade, non-
purulent inflammation of variable degree.  While the resultant gross changes are obvious, the 
underlying biochemical pathways are complex and have not been fully elucidated. 
 
The Synovial Joint: Anatomy and Physiology 
 
Joint Structure and Function 
The diarthrosis, or synovial joint, facilitates movement.  The synovial joint is lined by the joint 
capsule, contains variable amounts of joint fluid, and the cartilage covering the articulating bones 
within the joint capsule is called articular cartilage.21  The joint capsule has a stabilizing, fibrous 
outer layer and an inner, vascular synovial membrane.  The synovial membrane produces 
synovial fluid.  Surfaces of the articulating bones are covered with hyaline cartilage. 
   
Cartilage Constituents 
Hyaline cartilage is an avascular, aneural, and alymphatic tissue found at the end of long bones.  
Adult articular cartilage is unvascularized as blood vessels and the surrounding adventitia would 
alter its mechanical properties.  Blood flow would be repeatedly occluded during weight bearing 
and subsequent reperfusion injury would cause repeated damage to the chondrocytes.22  
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Chondrocyte nutrition is derived primarily from the synovial fluid with some contribution from 
the subchondral blood vessels. 
 
Cartilage is composed of chondrocytes and extracellular matrix.  Chondrocytes occupy less than 
2 percent of articular cartilage by volume and produce and maintain the extracellular matrix.23  
The extracellular matrix distributes force over the underlying subchondral bone and provides a 
smooth, nearly frictionless surface that allows movement of the joint.  By weight, the matrix is 
composed predominantly of water (65-80%) in the form of filtered synovial fluid, collagen (20-
30%), and proteoglycans(5-10%).24 
 
Collagen fibrils impart tensile strength to articular cartilage and provide a framework for 
embedded proteoglycans and chondrocytes.  There are at least 19 different types of collagen.25-27  
Collagen fibrils are made of chained monomers of protein.  Each monomer is composed of three 
polypeptide α-chains arranged in a triple helix.28  The α-chains are repetitive glycine-X-Y amino 
acid sequences.  Different types of collagen have different combinations and modifications of the 
α-chains within the triple helix and short globular terminal sequences. 
 
Collagen type II is the predominant form (90%) of collagen in articular cartilage.29-31 The fibrils 
of type II collagen in cartilage form a three dimensional lattice network.  Type VI collagen is 
found in the pericellular region of the chondrocyte and is thought to help bind the cell surface to 
matrix collagen and proteoglycans, thus forming the chondron.32  Type IX collagen links 
collagen type II fibrils together and limits their separation by proteoglycan swelling and may 
bind proteoglycan molecules to collagen type II.25-27, 29, 33, 34  Type X collagen is found in 
hypertrophic cartilage during development and in the deep, calcified zone of adult articular 
cartilage.25, 35  Its function is undetermined. The function of type XI collagen is currently 
unknown, but it is found at the core of the same collagen fibrils as type II collagen.27, 35, 36  
   
The proteoglycans impart elasticity to articular cartilage.  A proteoglycan monomer consists of a 
core protein with covalently attached glycosaminoglycan (GAG) chains forming very large, 
aggregates with hyaluronate and link protein.  The common GAGs of articular cartilage are 
chondroitin sulfate and keratan sulfate.30  Due to carboxyl and sulfate groups associated with the 
disaccharides, the GAGs are negatively charged. This negative charge causes the GAGs to 
remain separated when attached to the core protein, resulting in the molecule occupying a large 
area.  Proteoglycans have a strong affinity for water and can occupy a volume up to 50 times 
their dry weight volume when hydrated.37  The combination of the polyanionic nature of the 
GAGs and excess of molecules in cartilage matrix compared with external solution results in an 
osmotic gradient that contributes to the hydrophilic properties of proteoglycan.38, 39  Proteo-
glycans are normally contained within a meshwork formed by collagen fibrils.  The collagen 
framework limits the ability of the proteoglycans to expand and retains the individual 
proteoglycan to within 20% of its potential volume.37  This pressure, caused by the swelling, 
keeps the cartilage turgid, helping to resist deformation when a compressive load is applied. 
 
Aggrecan is the major proteoglycan of articular cartilage.  It consists of a long core protein with 
three distinct globular domains.  Many aggrecan monomers, stabilized by a link protein40, attach 
to a hyaluronic acid chain to form an aggrecan aggregate which give it its classic bottle-brush 
appearance.  An aggrecan aggregate from articular cartilage may contain over 100 aggrecan 
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monomers.41  Aggrecan aggregates are of various lengths, depending on the condition and 
location of the cartilage.42 
   
Hyaluronan is a GAG, although it is not sulfated and does not bind to a core protein like 
chondroitin and keratan sulfate. Hyaluronan consists of a repeating disaccharide of glucuronic 
acid and N-acetyl-glucosamine.  Because of its extended conformation, hyaluronan is highly 
hydrated.  Hyaluronan is an important component of both the articular cartilage matrix and 
synovial fluid and is produced by both chondrocytes and type B synoviocytes.43  In the matrix, 
hyaluronan plays a central role in tissue structure through interactions with aggrecan, link 
protein, and type VI collagen.44  As a cell surface matrix element, it is present on the cell surface 
in both a receptor-bound form and as a membrane component.  Synovial fluid hyaluronan is a 
boundary lubricant for soft tissues but does not function in cartilage-on-cartilage lubrication.29, 38  
 
Articular Cartilage Morphology 
The differences among connective tissues such as bone, skin, and cartilage are, in part, 
dependent on variations in the size, orientation, and packing of collagen fibrils.28  Collagen fibril 
orientation is important for articular cartilage function.  Articular cartilage morphology can be 
described using a zonal pattern.  The zonal pattern is based on chondrocyte organization, 
collagen fiber orientation, and proteoglycan distribution.23 
 
Zone 1, the superficial layer or tangential layer, has low cellularity and little proteoglycan 
content.  Collagen fibrils are oriented parallel to the articular surface.  The tangentially oriented 
collagen fibrils of zone 1 have the greatest ability to withstand high tensile stresses, thereby 
resisting deformation and distributing load more evenly over the surface of the joint.45 The 
orientation resists the swelling pressure exerted by proteoglycans of the deeper zones.45 
 
Zone 2, the transitional layer, is more cellular and has more proteoglycan content that zone 1.  
Collagen fibrils are obliquely oriented.  Zone 2 fibrils may alter their alignment under 
compression.  By decreasing the lattice pore size and increasing resistance to fluid flow through 
the cartilage it provides maximal resistance against load. 46-48 
 
Zone 3, the radial layer or deep zone, is the major portion of the cartilage matrix. Chondrocyte 
density and proteoglycan content are greater than zone2, and cells tend to be arranged in radially 
aligned vertical columns.  The high concentration of proteoglycan in zone 3 allows it to 
withstand compressive loads.45 
 
Zone 4 is the calcified cartilage layer. This zone contains radially oriented collagen fibrils but 
little proteoglycan. The calcified cartilage layer is adjacent to and separated from the sub-
chondral bone by a cement line at the osteochondral junction.  The mineralized cartilage is held 
in place by the undulating, interdigitating contours that allow shear stresses to be converted into 
more desirable compressive forces on the subchondral bone.49 
   
Interaction of Collagen and Proteoglycan 
The combination of collagen fibrils and proteoglycan forms a fiber-reinforced composite 
material that allows articular cartilage to withstand forces. Both collagen and proteoglycans 
contribute to load carriage in normal cartilage.50, 51 Collagen fibrils alone cannot sustain 
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compressive forces without collapse but tolerate tensile force well because of the interconnecting 
fibrils.52  Hydrated proteoglycan complexes are weak in shear but resist compressive force.53, 54 
When combined, the dynamic tissue is able to tolerate high compressive and shear loads.  If the 
connections between interconnecting fibrils break, propagation of fissures in articular cartilage 
will occur, leading to the morphologic changes characteristic of OA.55  The combination of 
collagen fibrils and hydrated proteoglycans is necessary. 
 
When cartilage experiences a compressive load, synovial fluid moves slowly within the cartilage 
matrix. Fluid flow through the extracellular matrix is dependent on the density of collagen lattice 
and the density of proteoglycan molecules.38  Synovial fluid is forced out of the cartilage until 
equilibrium is reached between the osmotic force generated by the proteoglycans and the 
compressive force applied.  Cartilage is stiff under rapidly applied loads since synovial fluid 
displaces slowly in the cartilage matrix, but cartilage is compliant compliant during less rapid 
loading.56  When the pressure is removed, the fixed negative charge attracts the water component 
of synovial fluid and the cartilage regains its pre-compressed thickness. Under most cir-
cumstances, the flow of synovial fluid, under pressure, allows articular cartilage to compress 
under load without permanent damage to its matrix.48  The mass movement of synovial fluid also 
allows the ridding of metabolic waste and acquisition of nutrition and oxygen. 
 
Articular cartilage adapts to the predominant stress.57  Cellular deformation occurs with 
mechanical stress and that this may be the source of signal transduction that leads to cartilage 
adaptation.58  Chondrocyte deformation may also incite the release of factors that activate 
degradative enzymes.  Degradative enzymes may be the mechanism for matrix change and 
destruction perhaps leading to OA. 
 
Etiopathogenesis of Osteoarthritis 
 
The actual cause of OA is unknown, but much is known about the changes in the structure and 
biochemistry of the cartilage.30  When the normal matrix, is disrupted, the function of articular 
cartilage is altered, leading to the changes typical of OA.2  There are at least two theories on the 
causes of the changes seen in OA.59  Primary OA, primary disease of the articular cartilage, is 
pathology of the cartilage structure.  Secondary OA indicate that the cartilage itself is normal.  
However, the changes seen within the cartilage have an etiology other than from the cartilage 
structure. Most OA is probably caused by a combination of both primary and secondary 
abnormalities. 
 
Primary OA is caused by abnormal cartilage or cartilage constituents.  Conditions that cause 
abnormalities in cartilage include advanced age, exposure to toxins, immune mediated disease, 
metabolic diseases, and genetic deficiencies.60  Collagen biosynthesis follows a pattern of nucle-
ated growth.  A few molecules are first assembled into a structure defined as a nucleus. The 
structure of the nucleus is then propagated by the orderly and rapid addition of thousands of the 
same molecules.61, 62  Because collagen biosynthesis is by nucleated growth, mutations that 
change the amino acid sequence of the protein have a profound affect on cartilage formation.  
Abnormalities in collagen synthesis are seen in such diseases as cutaneous asthenia, scurvy, 
hemochromatosis, ochronosis, chondrocalcinosis and Wilson’s Disease.26, 63, 64  Epidemiologic 
studies support genetics as causes of OA.65-67  Mutations in type IX or XI collagens are 
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associated with exposure and degradation of type II collagen and very early onset OA.68  Mice 
deficient in type IX collagen develop articular cartilage change typical of OA.69 
 
Secondary OA is caused by abnormal stresses being placed on normal cartilage.  Increases in 
forces associated with OA, are seen in obesity, developmental and anatomic abnormalities, 
following loss of joint stability, and in trauma.  Traumatic causes include an abnormal force on a 
normal joint (exogenous trauma, typified by articular fracture or joint luxation), a repetitive 
normal force on a normal joint (during excessive exercise) or a repetitive sub-normal to normal 
force on an unstable joint (occurring secondary to a developmental condition such as hip 
dysplasia or following cranial cruciate ligament rupture).  In a majority of dogs, articular 
cartilage remains healthy despite being subjected to substantial compressive forces during 
normal activity. 70, 71    Joints are protected from excessive unit load (force per unit area) by at 
least four mechanisms.  Muscle contraction is an active mechanism that transmits stress away 
from the joints.  Three passive mechanisms are transfer of forces into surrounding soft tissue, 
ligaments and muscles; joint incongruity, that allows increasing contact with increasing load; and 
compliance of the cartilage / cancellous bone unit.  When one of the four protection mechanisms 
is disturbed, cartilage damage occurs with resultant secondary OA. 
 
Muscle Contraction - The magnitude of the intra-articular forces depends on what the 
functional activity is, how the activity is performed, and how fast it is performed.72-76 Muscle 
activity at all joints during common activities appears to be dictated by fixed, neurologic 
responses, so-called locomotion or pattern generators, located in the brainstem.77  The speed at 
which an activity is carried out can be controlled voluntarily by the higher cortical centers. The 
locomotion generators and cerebellum coordinate these motions. This may have important 
implications in the cause of OA. Rapidly compressed synovial fluid has no time to flow, and 
matrix can be damaged.  By decelerating the limb just before it is about to hit an object 
impulsive loading is minimized. This momentary deceleration avoids the matrix micro damage 
that is found in osteoarthritic tissues.78-80 
 
Joint Incongruity - The breakdown of a mechanical structure depends on two important factors: 
the total force applied and the area over which it is loaded. The flaring of the ends of bones 
increases contact area.  The menisci increase contact area in the stifle.81  At the hip the concave 
acetabulum, under low loads, contacts the head of the femur about its periphery.  As the load 
increases, the acetabulum spreads and the femoral head flattens to increase the coxofemoral 
contact area.82, 83  Movement of the marrow and slight bending of the acetabular and femoral 
head trabeculae allow subchondral deformation without matrix damage.84 
 
Compliance of the Cartilage / Bone Unit - Cartilage is constructed in an ideal way to withstand 
compressive stresses.85-87  The subchondral trabecular boney bed on which the cartilage sits also 
absorbs some of the impulsive loading.88, 89  The articular cartilage rests on a layer of calcified 
cartilage, supported by a subchondral bone plate. This plate is supported by subchondral 
trabecular bone whose lattice arrangement follows the major stress trajectories of the transmitted 
load.31 The density of trabecular bone is related to the force of the repeatedly transmitted load.  
Trabecular bone is ten times more compliant than cortical bone,90 and micromotion of the 
subchondral trabecular bone and subchondral plate aids in joint conformation under load and 
may help absorb impulsive loads if they are not applied too quickly.55, 91, 92   
5 
  
Repetitive, impulsive loading, such as that seen in canine hip dysplasia due to joint laxity, will 
damage the matrix.93 Although cartilage is very compliant, the normal thickness is unable to 
deform adequately to absorb impulsive loads.88 During impulse loading, the compressive load is 
applied too rapidly for the synovial fluid to flow and the cartilage matrix structure fails.94  Under 
very high rates of loading, there is insufficient time for cartilage deformation and marrow flow 
and the trabecular bone can be subjected to microdamage. This microdamage can accumulate 
and lead to fatigue failure.94 In an attempt to adapt to the stress, the repair of the subchondral 
bone damage stiffens and rearranges the trabecular structure.95  This process also turns on once 
dormant endochondral ossification, which duplicates the tidemark base on which the articular 
cartilage rests. As the ossification front advances, the articular cartilage is thinned. This thinning 
increases the shear stress on the articular cartilage, particularly in the deep zone, which can lead 
to fragmentation.96 In OA, there is extensive cartilage remodeling and degradation beyond 
fragmentation caused by physical trauma or structural abnormalities.  There appears to be a 
enzymatic pathway leading to terminal disruption of articular cartilage and periarticular tissues.97 
 
THE MATRIX METALLOPROTEINASES 
   
Discovery, Definition and Structure 
 
Proteolytic enzymes cleave either terminal (exopeptidases) or internal (endopeptidases) peptide 
bonds.  Endopeptidases are classified as serine, cysteine, aspartic or metalloproteinases based on 
their catalytic mechanisms.  More than 200 metalloproteinases have been described.  The 
metalloproteinases are divided on the basis of their 3-dimensional shape into 5 superfamilies and 
further into 40 families.  The metzincin superfamily has a highly conserved triple zinc catalytic 
site with a conserved methionine turn adjacent the active site.98  The matrix metalloproteinases, 
also known as and “matrixins” comprise family M10 of the metzincin superfamily.  Other 
members of the metzincin superfamily are the serralysins, a disintegrin and metalloproteinase 
(ADAM), a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and 
astracins.98 
 
Gross and Lapière recognition the first MMP in 1962, when isolated the enzyme responsible for 
tail resorption during frog metamorphosis.99  Currently there are at least 25 members of the 
MMP family found in vertebrates.100  The human genome project has identified or verified all 23 
human MMPs.  MMPs have been identified in non-vertebrates and in plants.101, 102 
 
The common features of the MMP family members are100: 1) the presence of zinc at the active 
site of the catalytic domain, 2) synthesis of the MMPs as a pro-enzyme that is secreted in an 
inactive form, 3) activation of the latent zymogen in the extracellular space, 4) recognition and 
cleavage of the extracellular matrix by the catalytic domain of the enzyme, and 5) inhibition of 
the enzyme action by both serum-borne and tissue-derived metalloproteinase inhibitors (TIMPs) 
in the extracellular environment. 
 
Basic MMP structure, shown in figure 1.1, consists of the following domains: 1) signal peptide – 
to direct MMPs in the secretory pathway, 2) prodomain – conveys latency to the enzyme by 
occupying the active site zinc molecule making the catalytic enzymes inaccessible to substrates, 
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3) zinc containing catalytic site, 4) hemopexin domain that mediates interactions contributing to 















Figure 1.1.  MMP Domain Structure 
 
There are exceptions to the basic molecular shape.  The active sites of MMP-2 and MMP-9 
contain an additional fibronectin-like domain.103  MMP-7, MMP-23, and MMP-26 lack a 
hemopexin domain.104  The membrane-type MMPs (MMP-14 through -17, -24, -25) contain an 
additional  transmembrane domain that binds them to the cell surface.105  The C-terminal end of 
MMP-23 is similar to an interleukin-1 receptor.106 
 
Naming Conventions and Groupings 
 
On the basis of substrate specificity, sequence similarity, and domain organization, MMPs can be 
divided into 6 groups: 1) Collagenases, 2) Gelatinases, 3) Stromelysins, 4) Matrilysins, 5) 
Membrane-type MMPs, and 6) Unique MMPs. 
 
Collagenases (MMP-1, MMP-8, MMP-13) 
The collagenases are MMP-1, MMP-8, and MMP-13.  The collagenases have the unique ability 
to disrupt the triple helix structure of collagen.  The collagenases have high affinity for a specific 
site ¾ from the N-terminus of interstitial collagen types I, II, and III.107  MMP-1 is expressed by 
fibroblasts, keratinocytes, endothelial cells, monocytes, macrophages, chondrocytes and 
osteoblasts.108  MMP-1 preferentially degrades collagen type-III.  MMP-8 is produced primarily 
by neutrophils.  The molecular weight of MMP-8 is higher than that of MMP -1.  The difference 
may account for targeting signals that direct the MMP-8 pro-enzyme to storage granules.108  
Transcription of mRNA and the production of proteins is slow taking six to 12 hours.  The 
storage of MMP-8 by neutrophils allows a sudden burst of MMP release when triggered without 
the need for transcription.  MMP-8 preferentially degrades collagen type-I.  The activity of 
MMP-8 is significantly higher (10 to 30-fold) than that of MMP-1.108, 109  MMP-13 expression is 
absent to minimal in normal adult tissues - it is expressed in bone and cartilage during 
development and by OA chondrocytes.110, 111  MMP-13 is activated by MMP-14 and that 
activation is enhanced by the presence of MMP-2112  MMP-13 has been shown to be involved in 
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remodeling of OA cartilage.113, 114 MMP-13 cleaves type-II collagen at least 10 times faster than 
MMP-1.112, 115, 116 Human and mouse MMP-1 appears to be induced differently.117 
 
Gelatinases (MMP-2, MMP-9) 
The gelatinases are MMP-2 and MMP-9.  The gelatinases readily digest denatured fibrillar 
collagen but have no effect on the intact helices.  MMP-2 is produced by a very large number of 
cell types including fibroblasts, keratinocytes, chondrocytes, endothelial cells and in transformed 
cells.  The transcription of MMP-2 appears to be constitutive and not very responsive to 
cytokines.118  MMP-9 is produced by keratinocytes, monocytes, macrophages and neutrophils, 
and carcinoma cells.119   
 
Stromelysins (MMP-3, MMP-10) 
The stromelysins are MMP-3 and MMP-10.  MMP-3 has a fairly broad range of substrates 
including type IX collagen - the collagen responsible for cross-linking of type-II fibrillar 
collagen. MMP-3 and MMP-10 have similar specificities with MMP-3 having a much higher 
activity on all known substrates.  MMP-3 is produced by stromal cells, including chondrocytes.   
 
Matrilysins (MMP-7, MMP-26) 
The matrilysins, MMP-7 and MMP-26,  are produced exclusively by neoplastic cells120, 121 and 
participate in invasion and metastasis. 
 
Membrane-type MMPs (MMP-14 through -17, MMP-24, MMP-25) 
The membrane-type MMPs (MT-MMPs) consist of four type-I transmembrane proteins (MMP-
14, MMP-15, MMP-16, and MMP-24) and two glycosylphosphatidylinositol(GPI) anchored 
proteins (MMP-17 and MMP-25).  The MMP-14, MMP-15, and MMP-17 are produced by 
neoplastic cells, chondrocytes, and fibroblasts.  The remainder of the MT-MMPs are produced 
by cells of the central nervous system, including glioma cells.122  MT-MMP activity is regulated 
by cytoplasmic control of endocytosis.  MT-MMPs are transcribed and secreted onto a cell’s 
surface when needed and internalized via endocytosis in clathrin-coated vesicles when down-
regulation is required.123  The cytoplasmic domains of the MT-MMPs may also play a role in 
regulation by limiting the number of active molecules exposed to the pericellular environment.123  
MT-MMPs have been implicated in invasion of neoplastic cells into the surrounding matrix via 
remodeling of type-I collagen and reduced cellular adhesion.107, 124, 125 
 
Unique MMPs 
The unique MMPs are not classified in the above categories.  MMP-11 (stromelysin 3) is 
produced by neoplastic stromal cells and degrades proteoglycans and gelatins.  MMP-12, 
macrophage metalloelastase, is produced by macrophages and degrades primarily elastin 
allowing macrophage migration.  MMP-18 (Xenopus collagenase-4 or XMMP) is found in 
metamorphosing tadpoles.126  MMP-19 (RASI-1) has been isolated in ovarian ligaments, 
synovial endothelial lining of rheumatoid arthritis patients, and in mononuclear inflammatory 
cells127.  MMP-20 (enamelysin) is produced by enameloblasts in budding teeth and has the 
capability to degrade amelogenin.128  MMP-23 (Cysteine Array MMP) is produced by the ovary, 
testis, and prostate.129  The in vivo substrates of MMP-23 are unknown.  The substrates of MMP-
27 (Gallus CMMP) are unknown.  MMP-28 (epilysin) is expressed by keratinocytes and may 
function in wound repair and hemostasis.130, 131 
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MMP-4, MMP-5, MMP-6, and MMP-29 are redundant as they were minor genetic variations of 
other MMPs.  MMP-21 and MMP-22 are now recognized as MMP-23A and MMP-23B. 
 
Substrate Specificity 
In general, MMPs cleave a peptide bond just before a hydrophobic side chain (i.e. leucine or 
tyrosine).  The hydrophobic residue must fit within the active site of the MMP and other contact 
sites participate in the reaction.  The active site seems forgiving, as most MMPs have a broad 
range of substrates on which they act in vitro.  Very few in vivo substrates have been identified.  
Due to the high degree of overlap in substrate activity and specificity, a move away from the 
above-stated grouping convention has occurred.  Though MMPs are still referred to by name, 
using MMP number may be more appropriate. 
 
The Role of MMPs in Health 
 
It is important to realize that most of the evidence linking MMPs with proposed roles in both 
health and disease is indirect.  In vivo studies modulating the expression of a single MMP gene, 
until recently, are rare.  Most of the evidence of the roles MMPs play is circumstantial (i.e. 
elevation of MMP activity or concentrations in certain disease states or the in vitro activity of an 
enzyme on a substrate).  However, with the completion of the human genome project all human 
MMPs have been identified.  With subsequent identification of homologous genes in other 
species, in vivo studies using single gene manipulation, will be forthcoming. 
 
MMPs are proposed to have integral roles in embryonic development, organ morphogenesis, 
angiogenesis, bone and cartilage remodeling, wound healing, periodontal integrity, corneal 
repair, and inflammation.100, 132, 133  Most cells adhere to a matrix that is required for cellular 
survival.  MMPs act to disrupt subcellular matrices inducing apoptosis as in involuting mammary 
glands.134, 135  MMPs effect cell-to-cell communication by altering the physical pericellular 
environment and releasing cytokines sequestered by the ECM.  Substrates for MMPs include not 
only the ECM but also a large number of non-ECM molecules including proTNF-α, proIL-1ß, 
plasminogen and other MMPs.  MMPs through degradation of the ECM may alter cellular 
behavior producing phenotypes.  In addition MMPs may activate or inactivate paracrine signals 
directly.136 
 
In wound healing, keratinocyte migration across collagen-1 requires the cleaving of collagen by 
MMP-1.137  MMP-3 appears to have a role in fibroblast-mediated wound contraction.138, 139  
Increased MMP-3 to TIMP-1 ratio however, may be responsible for chronic non-healing 
wounds.140  MMPs participate in the extensive remodeling of the ovary and uterus and are 
regulated by cyclic hormonal fluctuations.100  MMP-3 has been shown to be instrumental in 
resorption of herniated disc material.141-143  In mice, the inactivation of MMP-9 transcription or 
absence of MMP-13 leads to failure of endochondral ossification.133, 144  In MMP-14 null 
animals, numerous skeletal abnormalities, including dwarfism, occur.145   
9 
The Role of MMPs in Disease 
 
MMP expression is low in normal cells.  Low levels of MMPs allow for connective tissue 
remodeling.  Overproduction of MMPs (in comparison to inhibitor concentrations) has been 
implicated in diseases such as arthritis, cancer, tissue ulceration, periodontal and inflammatory 
bowel diseases.   
 
Neoplasia - Degradation of the extracellular matrix is an essential step in neoplastic cell invasion 
and metastasis.124, 146  MMPs likely play a part in that matrix degradation.  Neoplastic cells may 
be responsible for induction of MMP secretion by neighboring stromal cells.147, 148  An 
extracellular matrix metalloproteinase inducer (EMMPRIN) is produced in high amounts by 
neoplastic cells.  EMMPRIN, a plasma membrane glycoprotein, stimulates local fibroblasts and 
other stromal cells to synthesize MMP-1, MMP-2, and MMP-3.149  The in situ overexpression of 
MMPs has been utilized to determine malignancy116, 146 and metastasis.150, 151  Tumor-associated 
trypsinogen-2 has been shown to be associated with the malignant phenotype of neoplastic cells.  
Tumor-associated trypsinogen-2 activates MMP-1, -3, -8, and -13 contributing to basement 
membrane invasion and metastasis.152  Plasma concentrations of MMPs have been utilized to 
successfully predict metastasis and prognosis.151, 153, 154   
 
Dental Disease - MMPs released by neutrophils play a role in human and canine periodontal 
disease.155  MMP enzyme activity increases with disease severity.  Periostat®, doxycycline 
hyclate, is used to combat periodontal disease by inhibiting collagenase.156  It is the only licensed 
MMP inhibitor. 
 
Osteoarthritis - MMP-1157, -2158, -3159, 160, -7161, -8157, -9162, -13157, and MT-MMPs158 are 
expressed in osteoarthritic cartilage.  The primary histiologic change  in early OA is the loss of 
proteoglycans while collagen content remains near normal.163-165  MMP-3, a proteoglycan 
degrading enzyme, can be localized to the zones of cartilage with active proteoglycan 
depletion.159, 161  An imbalance in MMP concentrations and TIMP concentrations has been 
demonstrated in early OA cartilage.166  In normal human joints, the MMP-3:TIMP-1 ratio is 
about 0.5 indicating a relative excess of TIMP-1.167  MMP-3:TIMP-1 in OA cartilage has been 
found to be greater than 1, indicating a relative excess of MMP-3.168, 169  MMP-3 activity in 
explant cultures of articular cartilage from the lateral aspect of the lateral femoral condyles in 
dogs with cranial cruciate ligament ruptures is  4 - 16 times higher than in control dogs.170  In 
this same study, histiologic grading was also correlated with MMP-3 activity.170 
 
Interleukin-1 receptors (IL-1R) are significantly increased in OA chondrocytes.113, 171  Canine 
chondrocytes exposed to interleukin-1 (IL-1) appear to increase their production of MMP 
concentrations in vivo and in vitro.172  The concurrent presence of IL-1 and MMP-3 in OA 
cartilage has been noted especially at sites of cartilage erosion.173  Intra-articular injections of an 
IL-1R antagonist (IL-1Ra) can slow the progression of experimental OA.174, 175  Ex vivo cells can 
be transduced with the IL-1Ra gene rendering the cells resistant to IL-1 mediated degradation. 




Studies investigating MMP-3 as a cause of OA in mice are not in agreement.  When exposed to 
antigens that induce arthritis, MMP-3-deficient knock-out mice do not produce type-II collagen 
and aggrecan breakdown products as wild-type mice do.178  However, MMP-3 deficient and 
wild-type mice are equally susceptible to arthritis.179  The overlap of MMP substrate specificity 
may account for the difference. 
 
In early OA, MMP-3 is over-expressed, but it is down-regulated in the late stage OA.180  In late 
stage OA, MMP-2 and MMP-13 are up-regulated.180  MMP-13 activity has been shown to 
correlate with OA lesion severity.110  Transgenic mice that constitutively express MMP-13 
develop lesion similar to those found in OA.181  MMP-13 is important in OA cartilage 
degradation as it preferentially degrades type II and IX collagen.115  In mice that do not produce 
type IX collagen, type II collagen is exposed and particularly vulnerable to MMP-13 
degradation.68  The number of chondrocytes synthesizing MMP-1 and MMP-13 is increased in 
the early phases of OA.182  MMP-1 is found in higher concentration in the superficial cartilage; 
MMP-13 in the deeper layers of OA cartilage.182 
 
MMP-2 and MMP-9 are present in increased concentrations and activity levels in the synovial 
fluid of osteoarthritic joints of dogs.183, 184 
  
Other Arthritides - Concentrations and activity of MMP-1, MMP-3 and MMP-9 in the synovial 
fluid of people with rheumatoid arthritis (RA) is higher than that in people with OA.185-187  
MMP-3 activity is 100-fold higher in human RA synovial fluid than in control synovial fluid.188  
Plasma concentrations of MMP-3 are significantly increased in people with RA and SLE versus 
healthy controls.189  Serum MMP-3:TIMP-1 ratios were higher in people with RA than in people 
with undifferentiated arthritis.190  Increased MMP concentrations may reflect the severe 
inflammatory condition of rheumatoid arthritis.  Baseline serum MMP-1 and MMP-3 
concentrations have been correlated with progression of erosive disease in RA patients.191 
 
Collagenase activity is elevated in synovial fluid from people with RA.192  MMP-9 
concentrations in the synovial fluid and serum of people with RA is elevated about 3 times that 
of normal people.193  The cellular source of MMP-9 in RA is likely to be neutrophils, that are 
present in large numbers in RA pannus.184 
 
Chondrocyte cell cultures exposed to Borrelia burgdorferi over-express MMP-1 and MMP-3.194  
Similarly, in the synovial fluid of people with untreated Lyme disease, MMP-1 and MMP-3 
concentration are increased.  In antibiotic resistant Borrelia infections, MMP-8 and MMP-9 
concentrations are elevated.  Since MMP-8 and MMP-9 are present in neutrophils, the difference 
in MMP concentrations in resistant strains may indicate the presence of secondary immune-
mediated disease. 
 
The concentrations of MMP-1 and MMP-3 are increased in the synovium of children with 
juvenile idiopathic arthritis.195  The MMP concentrations correlate with degree of inflammation 
present.  The ratio of MMP-3:TIMP-1 was significantly increased in affected joints versus 




Regulation of MMPs 
 
For MMPs to function in health, they must be produced by the correct cell, secreted to the 
pericellular location at the correct time, in the correct concentrations and then activated or 
inhibited appropriately.  MMPs are regulated by: 1) DNA transcription, 2) cellular secretion, 3) 
furin or extracellular activation, 4) interaction with cell membranes and ECM components, 5) 
extracellular inhibition, and 6) clearance. 
 
DNA Transcription - The substrate specificity of MMPs is quite broad.  That is most MMPs 
degrade more than one substrate.  Also, more than one MMP degrades a particular substrate.  
Differential patterns of expression may dictate the unique roles of individual MMPs.136  With the 
exception of MMP-2 that is constitutively expressed, MMPs are tightly regulated at the 
transcription level.  MMP gene expression is controlled by numerous factors.  Interleukins, 
interferons, growth factors, tumor necrosis factor α (TNF-α), TNF-β, and EMMPRIN all 
increase MMP gene expression.196-198  Interleukins and TNF-β are increased in the osteoarthritic 
joints of dogs.199  Vascular endothelial growth factor (VEGF), known for its role in bone 
formation at the growth plate, is expressed by OA chondrocytes.  VEGF increases the production 
of MMP-1 and MMP-3 without increases in TIMP-1 or TIMP-2.200  Interestingly, some 
cytokines differentially influence transcription.  As an example, transforming growth factor β 
(TGF-β) induces the expression of MMP-13 but suppresses the transcription of MMP-3.113, 201, 202 
 
Cellular Secretion - MMPs are typically constitutively secreted once transcribed.  Exceptions 
are MMP-8 and MMP-9 that are stored in neutrophil granules until activation during 
inflammation.203 
 
ProMMP Activation - In order for a proMMP to be activated, the pro-domain cysteine-zinc 
pairing must be disrupted.  In vivo activation is likely via the proteolytic cleavage of the 
propeptide domain at the N-terminus of the molecule.204  The exact mechanisms of MMP 
activation are unknown with the exception of MMP-2.  The in vivo activation of MMP-2 requires 
the participation of MMP-14, TIMP-2 and an already activated MMP-2.205-207  Several serine 
proteases readily activate all MMPs except MMP-2.  Plasmin has been reported to activate 
proMMP-1, -3, -7, -9, -10, and -13.208  ProMMP-11, ProMMP-27, and MT-MMPs are activated 
intracellularly by furin, before being secreted.209  In these MMPs, gene expression is critical for 
regulation. 
 
Interaction with Cell Membranes and ECM Components - It has been proposed that vicinity 
to a cell surface is required for maximal MMP activity.210  MMPs associate with the cell surface 
glycoprotein attachment molecule 44 (CD44),211 intercellular adhesion molecule 1 (ICAM-1), 
integrins205 and EMMPRIN212 which are molecules closely associated with the cell surface.  By 
attaching to the cell surface, proteolytic activity may be concentrated where it is most needed and 
provide a mechanism to control and cell-to-cell signaling.  Changes in cell shape have been 
shown to induce MMP expression.213  Synoviocytes and fibroblasts increase the production of 
prostaglandin E2 and MMP-1 when in cell-to-cell contact with activated T-lymphocytes.214  T-




MMP Inhibition - MMP inhibition is by several endogenous compounds.  MMPs have 
approximately a 150-fold higher affinity for α2-macroglobulin than type-I collagen, suggesting 
that α2-macroglobulin may be a major regulator of collagenolysis.100  A membrane-anchored 
molecule, reversion-inducing cysteine-rich protein with Kazal motifs (RECK) appears to 
regulate MMP-2, MMP-9 and MMP-14 by affecting secretion as well as inhibition of the active 
site.215   
 
The four known tissue inhibitors of metalloproteinases (TIMPs) are the most studied of the MMP 
inhibitors.  The TIMPs are a family of small molecules that range from 21 to 29 kDa in size.  The 
TIMPs have about 50% sequence identity.  Their N- and C-terminus each contain three 
conserved disulfide bonds.  The N-terminus folds as a separate unit and is able to inhibit 
MMPs.216 TIMPs, stoichiometrically at a 1:1 ratio, reversibly bind and block MMP activity.  The 
expression and affinities of the TIMPs are all different.  There is recent evidence that TIMPs 
may also play a role in MMP activation.206 
 
TIMP-1 and TIMP-2 are present in many tissues and body fluids.216  TIMP-1 and TIMP-2 inhibit 
a broad range of MMPs.205  TIMP-1 is more efficient than TIMP-2 at inhibiting the gelatinases; 
TIMP-2 more efficient at inhibiting the collagenases.  TIMP-3 preferentially inhibits MMP-1, -3, 
-7, and -13.  It also blocks the metalloproteinase ADAM-17.217  TIMP-3 also has pro-apoptotic 
activity.218  TIMP-4 primarily inhibits MMP-2 and -7.  It has weak affinity for MMP-1, -3, and -
9.219  TIMPs appear to have roles other than MMP inhibition.  TIMP-1 has been located in rat 
sertoli cells and appears to stimulate steroidogenesis.220  TIMP-1 is also known as erythroid 
potentiating activity.221  TIMPs have been shown to inhibit angiogenesis222 and may both inhibit 
and potentiate tumor invasion.223 
 
Thrombospondin-2 binds and inhibits MMP-2.224  The role of thrombospondin-1 is not yet 
elucidated.  Thrombospondin-1 has been reported to bind proMMP-2 and proMMP-9 blocking 
their activation225 and increasing activitation.226   
 
Clearance - Little is known about the clearance of MMPs.  Macrophages, via scavenger 
receptors, clear α2-macroglobulin complexes.  Because α2-macroglobulin irreversibly binds 
MMPs, it is likely responsible for at least a portion of MMP clearance.205  Thrombospondin-2 
deficient mice have a wide range of connective tissue abnormalities and increased MMP-2 
concentrations. Thrombospondin-2 by its interaction with the scavenger receptor low density 




The MMPs are highly conserved across species.  The published homologies of MMP-3 between 
Homo sapiens and other species varies from 87.7% in the pig Sus scrofa to 79.4% in the Norway 
Rat Rattus norvegicus.227  The amino acid sequence of equine MMP-3 is 89% homologous with 
human MMP-3.228  In the Appendix, figures A.1 and A.2 compare human and canine MMP-3 
nucleic acid sequences and their subsequent amino acid translation.  The amino acid sequences 
are 81% homologous. 
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MMP-13 homology is 96.1% between Homo sapiens and the pig, Sus scrofa.227  In the 
Appendix, figures A.3 and A.4 compare human and canine MMP-13 nucleic acid sequences and 
their subsequent amino acid translation.  The amino acid sequences are 93% homologous. 
 
The homology of TIMP-1 comparing the cow Bos taurus and Sus scrofa is 90.8%.227  Canine 
TIMP-2 shares 96% of the human TIMP-2 protein at the amino acid level.229 In the Appendix, 
figures A.5 and A.6 compare human and canine TIMP-1 nucleic acid sequences and their 




Shortcomings of OA Research 
 
The study of OA can be accomplished by clinical evaluation of patients, radiographic studies, 
histomorphometric examination of the cartilage, the measuring of cartilage constituents (i.e. 
collagen, glycosaminoglycans, MMPs), the measuring of regulatory proteins (i.e. interleukins, 
TNF-α, TNF-β), or through the evaluation of the constituents of the periarticular environment 
(synovial fluid and synovium). 
 
Historically, most OA research has been conducted by direct examination of cartilage structure 
and measurement of cartilage constituents.  Attaining cartilage tissue samples without 
confounding subsequent observations is not possible.  Similar to the principal described by 
Heisenberg, I contend that the mere sampling of articular cartilage, to measure its constituents, 
changes the intra-articular environment so severely, as to render the joint unusable for future 
assays.  Drug trials of the cross-over design are, therefore, not possible because sequential 
sampling of a single subject is not possible.   
 
A preponderance of human and veterinary OA research utilizes induced, not naturally-occurring, 
OA.  Two models of osteoarthritis induction have been utilized in dogs.  In the method described 
by Pond and Nuki, the cranial cruciate ligament is transected inducing joint instability and 
subsequent OA.230 In the groove model as described by Marijnissen, et al.,231 the stifle joint is 
not destabilized.  Rather, articular cartilage is severely damaged to incite OA.  Though either 
model induces OA, because of the surgical approach, neither avoids also inducing synovial 
inflammation.  Neither model takes into account the chronic, low-grade inflammation that may 
actually contribute to or cause cruciate ligament rupture.  In addition, the breeds of dogs used in 
many studies are not those typically afflicted by naturally-occurring cranial cruciate ligament 
ruptures. 
 
Synovial Fluid as a Measure of Joint Metabolism 
 
Fluid in normal joints is present in small quantities; less than 1.0 mL in the 20kg canine’s 
stifle.232  The fluid is essential for the nutrition and lubrication of avascular articular cartilage.24  
Nutrients enter and waste products exit the cartilage by diffusion and during mass transport of 
fluid during compression-relaxation cycles.50  Solutes needed for cellular metabolism of the 
chondrocytes are small and readily pass through the collagen network.233  Intermittent 
compression may serve as a pump mechanism for solute exchange in cartilage.  Joint 
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immobilization or dislocation, preventing intermittent compression, leads to cartilage 
degeneration.234 
 
Synovial fluid is primarily an ultrafiltrate of plasma. Generation of this ultrafiltrate depends on 
the difference between capillary and intra-articular hydrostatic pressures and between colloid 
osmotic pressures of capillary plasma and synovial tissue fluid.  Fenestrations in synovial 
endothelium and the macromolecular sieve of hyaluronic acid permit the selective entry of water 
and low-molecular-weight solutes into the synovial fluid.235, 236  Plasma-borne proteins are 
present in synovial fluid in concentrations inversely proportional to molecular size.237 
 
Synovial fluid is cleared through lymphatics in the synovium, assisted by joint movement. 
Lymphatic clearance of solutes is independent of molecular size.  Constituents of synovial fluid 
may also be locally degraded by enzymes and low-molecular-weight metabolites may diffuse 
along concentration gradients into plasma. Clearance of synovial fluid and its constituents may 
be increased in inflamed joints as a result of increased lymphatic drainage, up-regulation of 
membrane peptidases, or increased synovial blood flow.238-240  Lymphatics may be damaged by 
severe inflammation and clearance of some synovial fluid components may be decreased.241 
Solutes in synovial fluid at higher concentrations than in plasma are likely to have been locally 
generated.  Synovial fluid and its constituent proteins have a rapid turnover time of about 1 hour 
in normal stifles.24  However, clearance rates from synovial fluid may be slower than those from 
plasma.  Synovial fluid concentrations of some drugs may remain elevated after plasma 
concentrations have declined.242  The turnover time for hyaluronan in the normal joint, about 13 
hours, is an order of magnitude slower than that of small solutes and proteins. Association with 
hyaluronan may therefore result in retention of solutes within synovial fluid.232 
 
Measurement of synovial fluid constituents to identify locally generated regulatory factors, 
markers of cartilage turnover, and the metabolic status of the joint has been investigated.168, 169, 
183, 238, 243-245  Because the volume of synovial fluid in the normal canine stifle is fairly small, 
information about the constituents of normal canine synovial fluid is sparse.  Comparisons of 
synovial fluid constituents between disease groups are often limited by the lack of data on 
normal synovial fluid.246  Comparing synovial fluid concentrations of constituents to the absolute 
amount of constituents made by the articular cartilage is complicated due to variations in 
clearance rates and in synovial fluid volume.  Trauma-induced OA and OA secondary to 
rheumatoid arthritis would certainly have different clearance rates and expected synovial fluid 
volume.  However, synovial fluid analysis may provide useful information about joint 
metabolism. 
 
Ideal Osteoarthritis Research Techniques 
 
The ideal methodology for studying OA would compare normal dogs with dogs in all stages of 
naturally-occurring osteoarthritis.  The diagnosis of OA is made on clinical signs and 
radiographic changes that occur late in the course of OA.  Early detection of OA may be possible 
by looking at markers of cartilage metabolism.247  Ideal sampling would not cause cartilage 
destruction and would be non-inflammatory.  Synovial fluid sampling, via arthrocentesis, is a 
minimally invasive procedure.  However, repeated arthrocentesis does cause minimal, short-
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lived increased MMP concentrations, presumably from synovitis.245, 248  In the horse, the effect is 
short-lived at less than 10 days and is less severe in larger joints. 
 
Studies, in dogs, have measured articular cartilage constituents and synovial fluid constituents, 
but none have reported an attempt to establish a relationship between the two.  If synovial fluid 
constituents are reflective of the metabolism of articular cartilage, then synovial fluid sampling 
could be utilized to sequentially assess the progression of OA and potentially the response to 
drug therapy. 
 
Quantification of enzymes can be accomplished via direct measurement or indirectly by 
measuring the products produced by the enzyme.  Direct measurement can be performed using 
antibodies that attach only to the enzyme of interest.  Indirect measurement can be accomplished 
by providing a substrate on which the enzyme can act.  Detection of the enzymatic action can be 
by measuring resultant product or reduction in substrate.  Methods can also be employed to 
circumstantially support the presence of an enzyme, like detecting the presence of a protein of 
the appropriate molecular weight. 
 
The measuring of canine enzymatic indicators of OA is not straight forward.  Antibodies against 
canine MMPs and TIMPs are not commercially available.   Antibodies against human MMPs 
have been utilized to detect canine enzymes in cartilage and in tumors.116, 160, 182  However, the 
assay sensitivity and specificity were not verified.  The proteins were separated by Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the masses matched to 
MMPs in humans.  Coupled with identification by human antibodies and the high degree of 
MMP/TIMP homology between the dog and human, it is reasonable to assume that the 
commercially available human antibodies would be able to detect canine enzymes.  With these 
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CHAPTER 2.  STUDY GOALS 
 
The goal of this study was to document the viability of measuring synovial fluid constituents that 
may characterize OA.  The long term goal would be to use measurement of these constituents as 
an adjunctive tool in diagnosis and evaluating anti-osteoarthritic therapeutics in dogs. 
 
The specific objectives of this study were: 
• To determine if it is possible to obtain via arthrocentesis sufficient quantities of synovial 
fluid to allow the measurement of its constituents for characterization of OA 
 
• To determine the concentration of Stromelysin-1 (MMP-3) in the synovial fluid and articular 
cartilage of the stifle in the normal dog 
• To determine the concentration of MMP-3 in the synovial fluid and articular cartilage of the 
osteoarthritic stifle in the dog 
• To compare the concentration of MMP-3 in synovial fluid with that found in the articular 
cartilage of the same joint 
• To determine if the concentration of MMP-3 in synovial fluid and articular cartilage is 
different in normal and osteoarthritic stifles in the dog 
 
• To determine the concentration of Collagenase-3 (MMP-13) in the synovial fluid and 
articular cartilage of the stifle in the normal dog 
• To determine the concentration of MMP-13 in the synovial fluid and articular cartilage of the 
osteoarthritic stifle in the dog 
• To compare the concentration of MMP-13 in synovial fluid with that found in the articular 
cartilage of the same joint 
• To determine if the concentration of MMP-13 in synovial fluid and articular cartilage is 
different in normal and osteoarthritic stifles in the dog 
 
• To determine the concentration of Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) in the 
synovial fluid and articular cartilage of the stifle in the normal dog 
• To determine the concentration of TIMP-1 in the synovial fluid and articular cartilage of the 
osteoarthritic stifle in the dog 
• To compare the concentration of TIMP-1 in synovial fluid with that found in the articular 
cartilage of the same joint 
• To determine if the concentration of TIMP-1 in synovial fluid and articular cartilage is 
different in normal and osteoarthritic stifles in the dog 
 
• To compare the MMP-3:TIMP-1 ratio in normal and osteoarthritic stifles 
• To compare the MMP-13:TIMP-1 ratio in normal and osteoarthritic stifles  
 
We hypothesized that the concentration of MMP-3 and MMP-13 in osteoarthritic stifles would 
be significantly greater than that in normal joints.  We hypothesized that the concentrations of 
MMP-3 and MMP-13 in synovial fluid would show a positive correlation with that in articular 
cartilage.  We hypothesized that the concentrations of TIMP-1 in synovial fluid would show a 
positive correlation with that in articular cartilage.  We hypothesized that the ratios of MMP-
36 
3:TIMP-1 and MMP-13:TIMP-1 would be statistically greater in osteoarthritic stifles than 
normal stifles. 
 
Because commercial assays are not available for measuring MMPs or TIMPs in dogs, finding 
and verifying assays was also a goal of this study.  
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This study was approved by the Institutional Animal Care and Use Committee of the Louisiana 
State University.  Dogs were selected from a pool of dogs being utilized for terminal, student 
surgery laboratories.  Dogs were selected based on the following criteria: 1) greater than 20kgs in 
body weight, 2) no signs of lameness, 3) no palpable joint effusion and 4) no overt signs 
systemic disease.  Synovial fluid was considered normal if the total white blood cell count was 
less than 1000/µL, the total protein concentration less than 2.5g/dL, it had a high viscosity and 
mucin clot test was considered good.1, 2  Breed and gender of dogs were recorded but did not 
affect the selection of subjects.  Rectal temperature, heart rate, respiratory rate, and the stifle 




Treatment of osteoarthritic dogs was approved by the Louisiana State University Clinical 
Protocol Review Committee.  Owner consent was attained prior to harvesting cartilage samples.  
Dogs were selected based on the following:  1) signs of lameness for more than 2 weeks, 2) 
radiographs of the affected joint were consistent with osteoarthritis and 3) synovial fluid analysis 
of the affected joint was consistent with degenerative joint disease.  The diagnosis of 
degenerative joint disease was made if total white blood cell count was less than 5,000/µL, the 
cell population was comprised primarily of mononuclear cells, total protein concentration was 
less than 3.5g/dL, with a moderate to high viscosity and a good mucin clot test.  Dogs with 
elevated total cell counts, increased percentage of neutrophils, elevated total protein 
concentrations, poor viscosity or a poor mucin clot test were not selected.  The diagnosis of 
degenerative joint disease was determined by the clinical pathologist on duty at the time of 
sample submission.  Dogs with cranial cruciate ligament rupture, the leading cause of OA in 
dogs3, were utilized as the osteoarthritic dogs.  Samples from dogs with other causes of 
osteoarthritis (i.e. femoral heads from dogs with hip dysplasia) were utilized only in assay 
development. 
 




Normal Dogs - Immediately after euthanasia, dogs were placed in dorsal recumbency with both 
rear legs hanging over the end of the table.  A flip of a coin was used to determine using either 
the left or right stifle.  The area surrounding the stifle was clipped and aseptically prepared.  If 
the attempt to acquire synovial fluid was unsuccessful, the procedure was repeated on the 
contralateral limb.  Synovial fluid was attained via direct arthrocentesis.  Aliquots for the study 
were placed in polypropylene screw cap micro tubes (72.694, Sarstedt AG & Co., Newton, NC).  
Within 15 minutes of harvest, the samples were frozen at -70C until assayed.  At least 0.4mL of 
synovial fluid was retained for assay.  The remainder of the sample, if available, was placed in a 
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potassium EDTA-coated, vacuum glass tube (Becton Dickinson Vacutainer Systems, Franklin 
Lakes, NJ) and submitted for fluid analysis. 
 
Osteoarthritic Dogs - Position of the dog was dependent on the joint being operated and 




Normal Dogs - After synovial fluid samples were attained, a medial arthrotomy was performed.  
Using Lempert rongeurs, full thickness articular cartilage was harvested from the cranial aspect 
of the medial condyle of the femur.  At harvest, no attempt to separate the subchondral bone was 
made.  Several samples were taken from each dog.  Two samples for microscopic examination 
were immediately placed in 10% formalin.  The reminders of samples for assay were stored in 
polypropylene screw cap micro tubes.  Within 15 minutes of harvest, the samples were frozen at 
-70C until assayed. 
 
Osteoarthritic Dogs - Cartilage samples were attained via arthrotomy in all cases.  Stifle 
samples were obtained from a non-weight bearing surface - the lateral surface of the lateral 
condyle or the medial surface of the medial condyle.  Femoral head samples were obtained from 
tissues excised during femoral head and neck ostectomy.  Samples of osteoarthritic joints, other 
than stifles, were used for assay development and were not used to compare groups.  All samples 




Tables 3.1 and 3.2 show the physical characteristics, cytologic analysis, and histopathologic 






Samples were allowed to equilibrate to room temperature.  To reduce viscosity, the samples were 
incubated at 25°C with 1000 units/mL of activated hyaluronidase (type I from bovine testes; 
Sigma, St. Louis, MO) for 1 hour prior to ELISA testing on 08/08/03 and 6 hours prior the 
ELISA assays run thereafter and prior to zymography.  Prior to Western blotting samples were 
incubated at 37°C for 24 hours.  The hyaluronidase was reconstituted using the prepared ELISA 
assay buffer prior to ELISA or using the manufacturer’s instructions (0.02 M phosphate buffer, 
77mM NaCl, 0.01% BSA at a pH of 7.0) before zymography or Western blot.  After incubation, 








Table 3.1. Samples from Normal Dogs.  Physical characteristics and cytologic examination of 
synovial fluid and histophathologic examination findings of articular cartilage for samples from 
normal canine stifles.  QNS = quantity not sufficient, samples “Not examined” have been 




Color Clarity Viscosity Cytologic Findings, Total White Blood 
Cell Count / μL, Protein in g/dL, Mucin 
Clot Test 
Histopathology 
N1 colorless clear high no abnormalities no abnormalities 
N2 colorless clear high no abnormalities no abnormalities 
N3 colorless clear high  no abnormalities 
N4 colorless clear high low grade neutrophilic inflammation no abnormalities 
N5 colorless, blood clear high acute hemorrhage no abnormalities 
N6 colorless clear high no abnormalities, , less than 2.5 no abnormalities 
N7 colorless clear high no abnormalities no abnormalities 
N8 colorless clear high no abnormalities not examined 
N9 colorless clear high no abnormalities not examined 
N10 colorless clear high degenerative arthropathy not examined 
N11 colorless clear high QNS, not performed not examined 
N12 colorless clear high no abnormalities not examined 
N13 colorless clear high QNS, not performed no abnormalities 
N14 colorless clear high no abnormalities no cartilage in sample 
N15 colorless clear high not submitted no abnormalities 
N16 colorless clear high QNS, not performed superficial cartilage 
erosion 
N17 colorless, blood clear high acute hemorrhage not examined 
N18 colorless clear high QNS, not performed not examined 
N19 colorless clear high QNS, not performed not examined 
N20 colorless clear high QNS, not performed not examined 
N21 colorless clear high QNS, not performed not examined 
N22 colorless clear moderate no abnormalities, 2100,  less than 2.5 not examined 
N23 colorless clear high QNS, not performed not examined 
N24 colorless clear high QNS, not performed not examined 
N25 colorless clear high QNS, not performed not examined 
N26 colorless clear high QNS, not performed not examined 
N27 colorless clear high QNS, not performed not examined 
N28 colorless clear high QNS, not performed not examined 
N29 colorless clear high QNS, not performed not examined 
N30 colorless clear high QNS, not performed not examined 
N31 colorless clear high QNS, not performed not examined 
N32 colorless clear high QNS, not performed not examined 
N33 colorless clear high QNS, not performed not examined 
N34 colorless clear high QNS, not performed not examined 
N35 colorless clear high no abnormalities, , less than 2.5 not examined 
N36 colorless clear high QNS, not performed not examined 
N37 colorless clear high QNS, not performed not examined 
N38 colorless clear high QNS, not performed not examined 
N39 colorless clear high QNS, not performed not examined 
N40 colorless clear high QNS, not performed not examined 
N41 colorless clear high QNS, not performed not examined 
N42 colorless clear high QNS, not performed not examined 
N43 colorless clear high QNS, not performed not examined 
N44 colorless clear high QNS, not performed not examined 
N45 colorless clear high no abnormalities, , less than 2.5 not examined 







Table 3.2. Samples from Osteoarthritic Dogs.  Physical characteristics and cytologic 
examination of synovial fluid and histophathologic examination findings of articular cartilage for 
samples from osteoarthritic canine stifles.  DJD = degenerative joint disease, QNS = quantity not 





Color Clarity Viscosity Cytologic Findings, Total White Blood 
Cell Count / μL, Protein in g/dL, Mucin 
Clot Test 
Histopathology 
OA1 colorless clear poor low grade neutrophilic inflammation, 3000, 
3.4, fair 
DJD 
OA 2 straw hazy poor DJD, 1200, 3.9, fair not examined 
OA 3 red hazy poor DJD, 2700, 3.2, good not examined 
OA 4 yellow hazy moderate DJD, 2000, 2.9, fair not examined 
OA 5 straw cloudy  DJD, 1400, 3.7 DJD 
OA 6 yellow hazy  DJD, 2400, 3.3, fair not examined 
OA 7 colorless clear moderate no abnormalities, , 4.2 not examined 
OA 8 yellow hazy good DJD, , 3.9, good not examined 
OA 9 straw hazy moderate DJD, 1800, 3.2, good not examined 
OA 10 colorless clear moderate QNS, not performed not examined 
OA 11 orange hazy good no abnormalities, 2800, 2.7, good not examined 
OA 12 straw hazy poor DJD, 1000, 3.5, poor not examined 
OA 13      
OA 14      
OA 15 orange clear moderate macrophage reactivity, 1400, 3.6, fair not examined 
OA 16 blood- 
tinged 
hazy good QNS, not performed no cartilage harvested 
OA 17 red clear good QNS, not performed no cartilage harvested 
OA 18 blood- 
tinged 
clear moderate QNS, not performed no cartilage harvested 
OA 19    QNS, not performed no cartilage harvested 
OA 20 straw clear  moderate QNS, not performed no cartilage harvested 
OA 21 straw clear  good  QNS, not performed no cartilage harvested 
OA 22 straw clear  moderate  not performed no cartilage harvested 
OA 23 straw clear  poor  not performed no cartilage harvested 
OA 24 straw clear  moderate  not performed no cartilage harvested 
OA 25 red hazy poor  not performed no cartilage harvested 
OA 26 straw  hazy  moderate  not performed no cartilage harvested 
OA 27 straw clear moderate  not performed 83733 not examined 
OA 28 straw clear moderate  not performed 83587 not examined 
OA 29 straw hazy moderate  not performed no cartilage harvested 
OA 30 blood-
tinged 





In order to retain all layers of articular cartilage, most of the subchondral bone was removed with 
rongeurs, leaving a thin layer attached to the deepest layers of the articular cartilage.  For ELISA 
testing, cartilage samples were allowed to equilibrate to room temperature and suspended by 
adding 0.2mL SDS and 0.2mL assay buffer to each sample.  Using a scalpel blade and Dounce 
tissue grinder, samples were ground until a homogenous substance remained.  The samples were 
centrifuged at 4000g for 10 minutes.  The supernatant was assayed.  For zymography and 
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Western blotting the samples were drowned in liquid nitrogen and powdered using a mortar and 
pestle.  The sample was suspended in loading buffer and homogenized by repeatedly drawing the 
sample through an 18-guage needle.  The sample was centrifuged at 4000g for 10 minutes.  The 
supernatant was assayed. 
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CHAPTER 4.  COMMERCIALLY AVAILABLE ELISA 
 
ENZYME-LINKED IMMUNOSORBENT ASSAY INTRODUCTION 
 
Enzyme-linked immunosorbent assay (ELISA) is a widely used technique for determining the 
presence or amount of protein in a biological sample.  A primary antibody is bound to a solid 
phase or plastic well.  The sample is introduced to the well and incubated allowing attachment to 
the antibody.  The well is washed, leaving behind only the attached protein being measured.  A 
secondary antibody (conjugated to a detection enzyme) is added to the well and incubated.  The 
well is again washed, leaving behind only the attached secondary antibodies.  A substrate is 
added to the well.  The conjugated enzyme, utilizing the available substrate, produces a 
detectable color change. Concentrations are calculated by comparing optical density to a set of 
known standards.  Commercially ELISA kits are available for detecting MMP-3, MMP-13 and 






MMP-3 concentration was measured using a double-antibody ELISA kit (RPN2613; Amersham 
Biosciences, Piscataway, NJ) designed for Human MMP-3.  The 96-well ELISA, depicted in 
figure 4.1,  utilizes a primary antibody to human MMP-3 and a horseradish peroxidase (HRP) 
labeled Fab’ antibody to human MMP-3.  Whether the antibodies are monoclonal or polyclonal 
is not advertised.  However, recognition of equine MMP-3, but not rabbit MMP-3, is claimed.  
The ELISA recognizes proMMP-3, active MMP-3 and MMP-3-TIMP complexes.  The MMP 
ELISA does not recognize MMP bound to non-specific inhibitors like α2-macroglobulin. 
Tetramethylbenzidine / hydrogen peroxide substrate (TMB) is utilized to determine the amount 
















Figure 4.1.  ELISA Design 
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The ELISA procedure was performed as per the manufacturers instructions (RPN2613PL Rev-A, 
Amersham Biosciences).  All reagents were allowed to equilibrate to room temperature 20-27°C 
before preparation.  Standards of 3.75, 7.5, 15, 30, 60 and 120 ng/mL were prepared by serial 
dilution of a 240 ng/mL stock solution.  One hundred μL aliquots of each standard were placed 
into 2 wells each.  Supplied assay buffer acted as 0 ng/mL standard.  Samples were distributed in 
100μL aliquots into 2 wells each.  The plate was incubated for 1 hour at 4°C.  All of the wells 
were washed 4 times with the wash buffer.  One hundred μL of peroxidase conjugate was added 
to each well.  The plate was incubated for 2 hours at 4°C.  All of the wells were washed 4 times 
with wash buffer.  TMB substrate was added to each well.  The plate was incubated for 30 
minutes at room temperature.  One hundred μL of 1 M sulfuric acid was added to each well.  The 
optical density of each well was read within 10 minutes at 450nm using an automatic plate reader 
(MRX TC Revelation, Dynex Technologies, Inc., Chantilly, VA).  Calculations of MMP-3 
concentrations were calculated by the plate reader software (Dynex Revelation 4.02, Dynex 





MMP-13 concentrations were measured using a double-antibody ELISA kit (RPN2621; 
Amersham Biosciences) designed for human MMP-13.  The ELISA utilizes two monoclonal 
antibodies to proMMP-13 and active MMP-13.  Procedures were similar to that stated above. 
Except, standards of 0.094, 0.19, 0.38, 0.75, 1.5 and 3 ng/mL were prepared by serial dilution of 




TIMP-1 concentrations were measured using a double-antibody ELISA kit (RPN2611; 
Amersham Biosciences) designed for Human TIMP-1.  The ELISA, utilizing a two monoclonal 
antibodies, recognizes both free TIMP-1 and TIMP-1 bound to MMP-1, MMP-2, MMP-3, and 
MMP-9.  Procedures were similar to that stated above.  Except, standards of 3.13, 6.25, 12.5, 25 




Samples collected before 08/08/03 were assayed.  Cartilage samples were resuspended with 
0.2mL SDS and then diluted with 0.2mL assay buffer.  Calculations of ng MMP-3 per ng sample 
= raw ng/mL ÷ (sample mass mg x 1000 ng/mg) x 0.4mL.  For use in the MMP-3 ELISA, 
synovial fluid samples were diluted 1:8 with assay buffer.  For use in the TIMP-1 ELISA, 
synovial fluid samples were diluted 1:32 with assay buffer as per ELISA manufacturer’s 
recommendations.  The assays were run with samples distributed on the 96-well plate as shown 




Additional samples collected up to that date were selected from and assayed.  Synovial fluid 
samples were diluted 1:1 with 2000 units/mL hyaluronidase in assay buffer.  The volume of 
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synovial fluid obtained from dogs OA10 & OA13 were small, 0.2 mL.  Twice the synovial fluid 
volume, 0.4 mL, of diluent was added to expand the volume.  The assays were run with samples 
distributed on the 96-well plate as shown in Table 4.7 – 4.9.  The results are shown in Table 4.10 
– 4.12.  Photographs of the plate are shown in Figures 4.2 – 4.4.   
 
Table 4.1.  MMP-3 ELISA Plate Layout for 08/08/03.  Columns 1 and 2 contain standards, the 
units are in ng/mL. N = normal, OA = osteoarthritis, SF = synovial fluid, C = cartilage, U = 
unused 
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Table 4.2.  TIMP-1 ELISA Plate Layout for 08/08/03.  Columns 1 and 2 contain standards, the 
units are in ng/mL. N = normal, OA = osteoarthritis, SF = synovial fluid, C = cartilage, U = 
unused 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
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Table 4.3 MMP-3 Concentrations in Cartilage Samples on 08/08/03.  * - indicates values 
were below the range of the standard curve, @ - cannot be calculated.  The standard values 




























ng MMP / 
ng sample
x 10-4
0  A1 0.160 0  A2 0.118 0   
3.75  B1 0.324 3.75  B2 0.213 3.75   
7.5  C1 0.182# 7.5  C2 0.378# 7.5   
15  D1 0.352# 15  D2 0.415# 15   
30  E1 0.643 30  E2 0.716 30   
60  F1 1.086 60  F2 1.201 60   
120  G1 1.933 120  G2 2.100 120   
N1 C 10 B3 0.142 * * B4 0.139 * * * 
N2 C 30 D3 0.153 * * D4 0.348 10.957 1.461 @ 
N3 C 20 F3 0.135 * * F4 0.296 7.612 1.522 @ 
N4 C 10 H3 0.126 * * H4 0.139 * * * 
N5 C 40 B5 0.268 5.822 0.582 B6 0.301 7.961 0.796 0.689 
N6 C 50 D5 0.184 0.367 0.029 D6 0.290 7.241 0.579 0.304 
N7 C 50 F5 0.214 2.348 0.188 F6 0.516 21.783 1.743 0.966 
N8 C 50 H5 0.151 * * H6 0.177 * * * 
N9 C 70 B7 0.342 10.571 0.604 B8 0.293 7.452 0.426 0.515 
N10 C 80 D7 0.562 24.768 1.238 D8 0.362 11.900 0.595 0.917 
N11 C 130 F7 0.598 27.098 0.834 F8 0.576 25.638 0.789 0.812 
N12 C 100 H7 0.845 43.018 1.721 H8 0.344 10.737 0.430 1.076 
OA1 C 10 B9 0.261 5.345 2.138 B10 0.154 * * @ 






















Table 4.4.  MMP-3 Concentrations in Synovial Fluid Samples on 08/08/03.   * - indicates 
values were below the range of the standard curve, @ - cannot be calculated.  The standard 






















0 A1 0.160 0  A2 0.118 0   
3.75 B1 0.324 3.75  B2 0.213 3.75   
7.5 C1 0.182# 7.5  C2 0.378# 7.5   
15 D1 0.352# 15  D2 0.415# 15   
30 E1 0.643 30  E2 0.716 30   
60 F1 1.086 60  F2 1.201 60   
120 G1 1.933 120  G2 2.100 120   
N1 SF A3 0.950 * * A4 0.141 * * * 
N2 SF C3 0.256 5.040 40.32 C4 0.163 * * @ 
N3 SF E3 0.097 * * E4 0.120 * * * 
N4 SF G3 0.096 * * G4 0.204 1.657 13.256 @ 
N5 SF A5 0.167 * * A6 0.199 1.354 10.832 @ 
N6 SF C5 0.203 1.616 12.928 C6 0.217 2.545 20.36 16.644 
N7 SF E5 0.189 0.746 5.968 E6 0.278 6.448 51.584 28.776 
N8 SF G5 0.299 7.832 62.656 G6 0.287 7.061 56.488 59.572 
N9 SF A7 0.297 7.665 61.32 A8 0.479 19.380 155.04 108.18 
N10 SF C7 0.345 10.797 86.376 C8 0.330 9.782 78.256 82.316 
N11 SF E7 0.594 26.838 214.704 E8 0.346 10.807 86.456 150.58 
N12 SF G7 0.400 14.327 114.616 G8 0.343 10.626 85.008 99.812 
OA1SF A9 0.602 27.316 218.528 A10 0.137 * * @ 




Table 4.5 TIMP-1 Concentrations in Cartilage Samples on 08/08/03.  * - indicates values 
were below the range of the standard curve, @ - cannot be calculated.  The calculated R2 of the 



























ng TIMP / 
ng sample 
0  A1 0.083 0  A2 0.065 0   
3.13  B1 0.192 3.13  B2 0.195 3.13   
6.25  C1 0.327 6.25  C2 0.311 6.25   
12.5  D1 0.579 12.5  D2 0.565 12.5   
25  E1 1.063 25  E2 1.042 25   
50  F1 1.955 50  F2 1.907 50   
N1 C 10 B3 0.063 * * B4 0.090 0.018 0.072 @ 
N2 C 30 D3 0.067 * * D4 0.088 * * * 
N3 C 20 F3 0.066 * * F4 0.075 * * * 
N4 C 10 H3 0.078 * * H4 0.097 0.198 0.792 @ 
N5 C 40 B5 0.071 * * B6 0.069 * * * 
N6 C 50 D5 0.087 * * D6 0.083 * * * 
N7 C 50 F5 0.072 * * F6 0.086 * * * 
N8 C 50 H5 0.078 * * H6 0.107 0.475 0.38 @ 
N9 C 70 B7 0.086 * * B8 0.101 0.325 0.186 @ 
N10 C 80 D7 0.082 * * D8 0.078 * * * 
N11 C 130 F7 0.082 * * F8 0.082 * * * 
N12 C 100 H7 0.088 * * H8 0.117 0.755 0.302 @ 
OA1 C 10 B9 0.058 * * B10 0.127 1.014 4.056 @ 





Table 4.6.  TIMP-1 Concentrations in Synovial Fluid Samples on 08/08/03.   * - indicates 
values were below the range of the standard curve, @ - cannot be calculated.  The calculated R2 






















0 A1 0.083 0  A2 0.065 0   
3.13 B1 0.192 3.13  B2 0.195 3.13   
6.25 C1 0.327 6.25  C2 0.311 6.25   
12.5 D1 0.579 12.5  D2 0.565 12.5   
25 E1 1.063 25  E2 1.042 25   
50 F1 1.955 50  F2 1.907 50   
N1 SF A3 0.062 * * A4 0.075 * * * 
N2 SF C3 0.066 * * C4 0.075 * * * 
N3 SF E3 0.064 * * E4 0.074 * * * 
N4 SF G3 0.068 * * G4 0.079 * * * 
N5 SF A5 0.067 * * A6 0.066 * * * 
N6 SF C5 0.069 * * C6 0.070 * * * 
N7 SF E5 0.068 * * E6 0.089 * * * 
N8 SF G5 0.070 * * G6 0.088 * * * 
N9 SF A7 0.095 0.148 4.736 A8 0.078 * * @ 
N10 SF C7 0.082 * * C8 0.075 * * * 
N11 SF E7 0.078 * * E8 0.085 * * * 
N12 SF G7 0.076 * * G8 0.087 * * * 
OA1SF A9 0.057 * * A10 0.085 * * * 





Table 4.7.  MMP-3 ELISA Plate Layout for 04/14/04.  All samples were synovial fluid.  
Columns 1 and 2 contain standards, the units are in ng/mL. N = normal, OA = osteoarthritis 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 N14 N14 N26 N26 N35 N35 N43 N43 OA7 OA7 
B 3.75 3.75 N15 N15 N27 N27 N36 N36 N44 N44 OA8 OA8 
C 7.5 7.5 N20 N20 N29 N29 N37 N37 N45 N45 OA9 OA9 
D 15 15 N21 N21 N30 N30 N38 N38 N46 N46 OA10 OA10 
E 30 30 N22 N22 N31 N31 N39 N39 OA3 OA3 OA11 OA11 
F 60 60 N23 N23 N32 N32 N40 N40 OA4 OA4 OA12 OA12 
G 120 120 N24 N24 N33 N33 N41 N41 OA5 OA5 OA13 OA13 
H N13 N13 N25 N25 N34 N34 N42 N42 OA6 OA6 OA14 OA14 
 
 
Table 4.8.  MMP-13 ELISA Plate Layout for 04/14/04.  All samples were synovial fluid.  
Columns 1 and 2 contain standards, the units are in ng/mL. N = normal, OA = osteoarthritis 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 N14 N14 N26 N26 N35 N35 N43 N43 OA7 OA7 
B 0.094 0.094 N15 N15 N27 N27 N36 N36 N44 N44 OA8 OA8 
C 0.19 0.19 N20 N20 N29 N29 N37 N37 N45 N45 OA9 OA9 
D 0.38 0.38 N21 N21 N30 N30 N38 N38 N46 N46 OA10 OA10
E 0.75 0.75 N22 N22 N31 N31 N39 N39 OA3 OA3 OA11 OA11
F 1.5 1.5 N23 N23 N32 N32 N40 N40 OA4 OA4 OA12 OA12
G 3.0 3.0 N24 N24 N33 N33 N41 N41 OA5 OA5 OA13 OA13
H N13 N13 N25 N25 N34 N34 N42 N42 OA6 OA6 OA14 OA14
 
 
Table 4.9.  TIMP-1 ELISA Plate Layout for 04/14/04.  All samples were synovial fluid.  
Columns 1 and 2 contain standards, the units are in ng/mL. N = normal, OA = osteoarthritis, U = 
unused 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 N14 N14 N26 N26 N35 N35 N43 N43 OA7 OA7 
B 3.13 3.13 N15 N15 N27 N27 N36 N36 N44 N44 OA8 OA8 
C 6.25 6.25 N20 N20 N29 N29 N37 N37 N45 N45 OA9 OA9 
D 12.5 12.5 N21 N21 N30 N30 N38 N38 N46 N46 OA10 OA10
E 25 25 N22 N22 N31 N31 N39 N39 OA3 OA3 OA11 OA11
F 50 50 N23 N23 N32 N32 N40 N40 OA4 OA4 OA12 OA12
G U U N24 N24 N33 N33 N41 N41 OA5 OA5 OA13 OA13
H N13 N13 N25 N25 N34 N34 N42 N42 OA6 OA6 OA14 OA14
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Table 4.10. MMP-3 Concentrations in Synovial Fluid Samples on 04/14/04.  The standard 
values marked with a # were not within 10%. Calculated values for the samples were not reliable 






















0 A1 1.226# 0  A2 0.441# 0   
3.75 B1 1.200# 3.75  B2 0.639# 3.75   
7.5 C1 2.207# 7.5  C2 1.238# 7.5   
15 D1 1.052 15  D2 1.030 15   
30 E1 1.936# 30  E2 1.104# 30   
60 F1 2.292 60  F2 2.353 60   
120 G1 3.003 120  G2 2.959 120   
N13 H1 1.324   H2 1.372    
N14 A3 0.477   A4 0.910    
N15 B3 0.519   B4 0.531    
N20 C3 0.358   C4 0.398    
N21 D3 0.347   D4 0.434    
N22 E3 0.558   E4 0.348    
N23 F3 0.423   F4 0.564    
N24 G3 1.062   G4 0.671    
N25 H3 1.474   H4 0.708    
N26 A5 1.267   A6 0.347    
N27 B5 1.355   B6 0.488    
N29 C5 1.083   C6 0.323    
N30 D5 1.642   D6 0.832    
N31 E5 2.393   E6 0.553    
N32 F5 2.314   F6 0.295    
N33 G5 2.215   G6 0.653    
N34 H5 3.191   H6 1.061    
N35 A7 0.122   A8 0.417    
N36 B7 0.198   B8 1.215    
N37 C7 0.192   C8 0.823    
N38 D7 0.293   D8 1.198    
N39 E7 0.165   E8 0.847    
N40 F7 0.254   F8 0.996    
N41 G7 0.273   G8 1.295    
N42 H7 0.305   H8 2.406    
N43 A9 0.382   A10 0.855    
N44 B9 0.798   B10 1.106    
N45 C9 0.266   C10 0.302    
N46 D9 0.945   D10 0.490    
OA3 E9 0.646   E10 1.440    
OA4 F9 0.385   F10 0.991    
OA5 G9 1.696   G10 1.924    
OA6 H9 0.535   H10 1.517    
OA7 A11 0.487   A12 0.968    
OA8 B11 0.433   B12 1.160    
OA9 C11 0.642   C12 0.894    
OA10 D11 0.462   D12 1.376    
OA11 E11 0.567   E12 1.262    
OA12 F11 0.602   F12 0.893    
OA13 G11 0.551   G12 1.754    






Figure 4.2 Photograph of the MMP-3 ELISA Results on 04/14/04.  Note dark (arrows) and 
light (white arrow) stripes indicative of inconsistent washing.  Also note the color pattern of the 
first 2 columns were not indicative of an appropriate standard serial dilution. 
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Table 4.11. MMP-13 Concentrations in Synovial Fluid Samples on 04/14/04.  The standard 
values marked with a # were not within 10%. Calculated values for the samples were not reliable 






















0 A1 2.810# 0  A2 2.158# 0   
0.095 B1 2.098# 0.095  B2 2.568# 0.095   
0.19 C1 2.666# 0.19  C2 2.380# 0.19   
0.38 D1 3.044# 0.38  D2 2.181# 0.38   
0.75 E1 2.599# 0.75  E2 2.101# 0.75   
1.5 F1 3.082# 1.5  F2 1.953# 1.5   
3.0 G1 3.033 3.0  G2 2.981 3.0   
N13 H1 3.077   H2 2.208    
N14 A3 3.014   A4 1.390    
N15 B3 1.162   B4 1.555    
N20 C3 1.563   C4 1.504    
N21 D3 2.256   D4 0.588    
N22 E3 2.876   E4 2.567    
N23 F3 2.132   F4 0.899    
N24 G3 3.004   G4 1.922    
N25 H3 2.954   H4 3.158    
N26 A5 1.168   A6 2.807    
N27 B5 1.591   B6 2.804    
N29 C5 1.502   C6 3.104    
N30 D5 1.326   D6 3.069    
N31 E5 2.619   E6 2.787    
N32 F5 2.624   F6 3.187    
N33 G5 3.126   G6 2.799    
N34 H5 3.181   H6 1.701    
N35 A7 0.857   A8 3.233    
N36 B7 0.610   B8 2.568    
N37 C7 0.298   C8 3.268    
N38 D7 0.439   D8 2.370    
N39 E7 0.333   E8 3.270    
N40 F7 0.149   F8 2.545    
N41 G7 0.176   G8 1.658    
N42 H7 0.577   H8 3.307    
N43 A9 0.604   A10 2.727    
N44 B9 1.072   B10 2.333    
N45 C9 1.422   C10 1.169    
N46 D9 0.959   D10 1.219    
OA3 E9 0.902   E10 1.413    
OA4 F9 1.444   F10 1.538    
OA5 G9 0.724   G10 1.223    
OA6 H9 0.552   H10 1.895    
OA7 A11 0.870   A12 0.281    
OA8 B11 0.449   B12 0.160    
OA9 C11 0.839   C12 0.281    
OA10 D11 0.526   D12 0.237    
OA11 E11 0.561   E12 0.161    
OA12 F11 0.590   F12 0.362    
OA13 G11 2.955   G12 0.351    







Figure 4.3 Photograph of the MMP-13 ELISA Results on 04/14/04. Note the color pattern of 




Table 4.12. TIMP-1 Concentrations in Synovial Fluid Samples on 04/14/04.  * - indicates 
values were below the range of the standard curve, @ - cannot be calculated.  The R2 of the 






















STD A1 0.056 0  A2 0.054 0   
STD B1 0.197 3.13  B2 0.176 3.13   
STD C1 0.347 6.25  C2 0.322 6.25   
STD D1 0.673 12.5  D2 0.636 12.5   
STD E1 1.205 25  E2 1.265 25   
STD F1 1.911 50  F2 2.082 50   
N13 H1 0.063 * * H2 0.056 * * * 
N14 A3 0.052 * * A4 0.065 * * * 
N15 B3 0.055 * * B4 0.073 * * * 
N20 C3 0.064 * * C4 0.060 * * * 
N21 D3 0.055 * * D4 0.079 * * * 
N22 E3 0.056 * * E4 0.053 * * * 
N23 F3 0.056 * * F4 0.053 * * * 
N24 G3 0.054 * * G4 0.053 * * * 
N25 H3 0.057 * * H4 0.062 * * * 
N26 A5 0.058 * * A6 0.062 * * * 
N27 B5 0.058 * * B6 0.056 * * * 
N29 C5 0.055 * * C6 0.06 * * * 
N30 D5 0.077 * * D6 0.057 * * * 
N31 E5 0.059 * * E6 0.053 * * * 
N32 F5 0.058 * * F6 0.056 * * * 
N33 G5 0.064 * * G6 0.064 * * * 
N34 H5 0.073 * * H6 0.067 * * * 
N35 A7 0.080 * * A8 0.078 * * * 
N36 B7 0.054 * * B8 0.055 * * * 
N37 C7 0.054 * * C8 0.059 * * * 
N38 D7 0.065 * * D8 0.061 * * * 
N39 E7 0.077 * * E8 0.063 * * * 
N40 F7 0.062 * * F8 0.056 * * * 
N41 G7 0.062 * * G8 0.061 * * * 
N42 H7 0.056 * * H8 0.057 * * * 
N43 A9 0.059 * * A10 0.117 0.224 * @ 
N44 B9 0.065 * * B10 0.091 * * * 
N45 C9 0.055 * * C10 0.084 * * * 
N46 D9 0.065 * * D10 0.106 * * * 
OA3 E9 0.072 * * E10 0.151 1.077 * @ 
OA4 F9 0.054 * * F10 0.088 * * * 
OA5 G9 0.067 * * G10 0.134 0.654 * @ 
OA6 H9 0.079 * * H10 0.176 1.732 * @ 
OA7 A11 0.109 0.012 * A12 0.095 * * @ 
OA8 B11 0.062 * * B12 0.071 * * * 
OA9 C11 0.067 * * C12 0.080 * * * 
OA10 D11 0.058 * * D12 0.082 * * * 
OA11 E11 0.063 * * E12 0.068 * * * 
OA12 F11 0.057 * * F12 0.065 * * * 
OA13 G11 0.057 * * G12 0.081 * * * 









Figure 4.4 Photograph of the TIMP-1 ELISA Results on 04/14/04. The first 2 columns show 




Samples from the previous day and newly thawed samples were run the following morning.  
Synovial fluid samples were diluted 1:1 with 2000 Units/mL hyaluronidase in assay buffer, 
except for sample OA3 that started with 1.2ml synovial fluid to which 0.8mL diluent was added.  
The assays were run with samples distributed as shown in Table 4.13 – 4.14.  The results are 
shown in Table 4.15 – 4.16.  Photographs of the plate are shown in Figures 4.4 – 4.5.  To verify 
that a substance in the synovial fluid was not interfering with the ELISA mechanism, aliquots of 
50μL of a sample and of 50μL of standard were added to each of 4 wells.  The resultant optical 
density (e.g. concentration) should have been (0.5 * concentration of sample) + (0.5 * 
concentration of standard).  Recovery of any other values would indicate interference by the 
sample.   
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Table 4.13.  MMP-3 ELISA Plate Layout for 04/15/04.  All samples were synovial fluid.  
Columns 1 and 2 contain standards, the units are in ng/mL. In wells A9 and B9 50μL of sample 
and 50μL of 30ng/mL standard were loaded.  In wells G10 and H10 50μL of sample and 50μL of 
120ng/mL standard were loaded.  N = normal, OA = osteoarthritis 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 N18 N23 N27 N31 N39 N44 OA3 
+30 
OA6 OA11 OA18 
B 3.75 3.75 N18 N23 N27 N31 N39 N44 OA3 
+30 
OA6 OA11 OA18 
C 7.5 7.5 N17 N22 N26 N30 N38 N43 OA3 OA5 OA9 OA17 
D 15 15 N17 N22 N26 N30 N38 N43 OA3 OA5 OA9 OA17 
E 30 30 N16 N20 N25 N29 N35 N41 N46 OA4 OA8 OA16 
F 60 60 N16 N20 N25 N29 N35 N41 N46 OA4 OA8 OA16 
G 120 120 N15 N19 N24 N28 N33 N40 N45 OA3 
+120 
OA7 OA12 





Table 4.14.  MMP-13 ELISA Plate Layout for 04/15/04.  All samples were synovial fluid.    
Columns 1 and 2 contain standards, the units are in ng/mL.  In wells A9 and B9 50μL of sample 
and 50μL of 0.75ng/mL standard were loaded.  In wells G10 and H10 50μL of sample and 50μL 
of 3.0ng/mL standard were loaded.  N = normal, OA = osteoarthritis 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 N18 N23 N27 N31 N39 N44 OA3 
+0.75 
OA6 OA11 OA18
B 0.094 0.094 N18 N23 N27 N31 N39 N44 OA3 
+0.75 
OA6 OA11 OA18
C 0.19 0.19 N17 N22 N26 N30 N38 N43 OA3 OA5 OA9 OA17
D 0.38 0.38 N17 N22 N26 N30 N38 N43 OA3 OA5 OA9 OA17
E 0.75 0.75 N16 N20 N25 N29 N35 N41 N46 OA4 OA8 OA16
F 1.5 1.5 N16 N20 N25 N29 N35 N41 N46 OA4 OA8 OA16
G 3.0 3.0 N15 N19 N24 N28 N33 N40 N45 OA3 
+3.0 
OA7 OA12







Table 4.15.  MMP-3 Concentrations in Synovial Fluid Samples on 04/15/04.  The standard 
values marked with a # were not within 10%, * - indicates values were low out of range of the 






















0 A1 0.152# 0  A2 0.116# 0   
3.75 B1 0.168 3.75  B2 0.172 3.75   
7.5 C1 0.229# 7.5  C2 0.402# 7.5   
15 D1 0.371# 15  D2 0.437# 15   
30 E1 0.699 30  E2 0.692 30   
60 F1 1.260 60  F2 1.275 60   
120 G1 2.360 120  G2 2.177 120   
N14 H1 0.100 *  H2 0.109 *   
N15 G3 0.121 *  H3 0.118 *   
N16 E3 0.122 *  F3 0.363 11.485  @ 
N17 C3 0.075 *  D3 0.092 *   
N18 A3 0.103 *  B3 0.102 *   
N19 G4 0.095 *  H4 0.415 14.417  @ 
N20 E4 0.117 *  F4 0.156 0.024  @ 
N22 C4 0.090 *  D4 0.103 *   
N23 A4 0.074 *  B4 0.079 *   
N24 G5 0.106 *  H5 0.092 *   
N25 E5 0.080 *  F5 0.139 *   
N26 C5 0.086 *  D5 0.091 *   
N27 A5 0.372 11.984 23.968 B5 0.190 1.925 3.850 #13.91 
N28 G6 0.296 7.784 15.568 H6 0.327 9.510 19.02 #17.29 
N29 E6 0.278 6.781 13.562 F6 0.205 2.750 5.500 #9.53 
N30 C6 0.149 *  D6 0.314 8.785  @ 
N31 A6 0.117 *  B6 0.134 *   
N33 G7 0.171 0.834  H7 0.096 *  @ 
N35 E7 0.228 4.029  F7 0.135 *  @ 
N38 C7 0.295 7.737 15.474 D7 0.170 0.779 1.558 #8.52 
N39 A7 0.195 2.167 4.334 B7 0.229 4.070 8.140 #6.24 
N40 G8 0.166 0.582 1.164 H8 0.168 0.688 1.376 1.27 
N41 E8 0.194 2.127  F8 0.099 *  @ 
N43 C8 0.114 *  D8 0.241 4.757  @ 
N44 A8 0.110 *  B8 0.145 *   
N45 G9 0.138 *  H9 0.128 *   
N46 E9 0.137 *  F9 0.124 *   
OA3 C9 0.135 *  D9 0.101 *   
OA3 + 
30 
A9 0.304 8.242  B9 0.218 3.446  #5.844 
OA3 + 
120 
G10 0.493 18.724  H10 0.352 10.893  #14.81 
OA4 E10 0.096 *  F10 0.142 *   
OA5 C10 0.094 *  D10 0.102 *   
OA6 A10 0.073 *  B10 0.069 *   
OA7 G11 0.194 2.119 4.238 H11 0.177 1.195 2.39 3.31 
OA8 E11 0.190 1.904  F11 0.151 *  @ 
OA9 C11 0.171 0.825  D11 0.094 *  @ 
OA11 A11 0.221 3.612  B11 0.147 *  @ 
OA12 G12 0.111 *  H12 0.092 *   
OA16 E12 0.158 0.101 0.202 F12 0.262 5.908 11.816 #6.01 
OA17 C12 0.150 *  D12 0.163 0.404  @ 







Figure 4.5 Photograph of the MMP-3 ELISA Results on 04/15/04. The first 2 columns are 
consistent with a standard serial dilution.  The wells containing both sample and standard are 
indicated by the arrows. 
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Table 4.16.  MMP-13 Concentrations in Synovial Fluid Samples on 04/15/04.  The standard 
values marked with a # were not within 10%, * - indicates values were below the range of the 
standard curve, @ - cannot be calculated; The average standard curve values were not reliable.  






















STD A1 0.147 0  A2 0.127 0   
STD B1 0.180# 0.095  B2 0.237# 0.095   
STD C1 0.296# 0.19  C2 0.379# 0.19   
STD D1 0.633# 0.38  D2 0.334# 0.38   
STD E1 0.559# 0.75  E2 0.471# 0.75   
STD F1 0.879# 1.5  F2 1.105# 1.5   
STD G1 1.742 3.0  G2 1.598 3.0   
N14 H1 0.086 *  H2 0.092 *   
N15 G3 0.122 *  H3 0.079 *   
N16 E3 0.065 *  F3 0.114 *   
N17 C3 0.113 *  D3 0.161 *   
N18 A3 0.090 *  B3 0.103 *   
N19 G4 0.055 *  H4 0.071 *   
N20 E4 0.057 *  F4 0.071 *   
N22 C4 0.069 *  D4 0.287 0.175  #@ 
N23 A4 0.111 *  B4 0.073 *   
N24 G5 0.133 *  H5 0.067 *   
N25 E5 0.117 *  F5 0.100 *   
N26 C5 0.128 *  D5 0.151 *   
N27 A5 0.063 *  B5 0.088 *   
N28 G6 0.233 0.065  H6 0.075 *  #@ 
N29 E6 0.079 *  F6 0.128 *   
N30 C6 0.067 *  D6 0.092 *   
N31 A6 0.074 *  B6 0.093 *   
N33 G7 0.156 *  H7 0.137 *   
N35 E7 0.059 *  F7 0.094 *   
N38 C7 0.067 *  D7 0.172 *   
N39 A7 0.147 *  B7 0.082 *   
N40 G8 0.072 *  H8 0.092 *   
N41 E8 0.087 *  F8 0.155 *   
N43 C8 0.090 *  D8 0.166 *   
N44 A8 0.104 *  B8 0.151 *   
N45 G9 0.102 *  H9 0.123 *   
N46 E9 0.101 *  F9 0.152 *   
OA3 C9 0.073 *  D9 0.229 0.057  #@ 
OA3 + 
30 
A9 0.171 *  B9 0.221 0.040  #@ 
OA3 + 
120 
G10 0.476 0.555 1.110 H10 0.515 0.632 1.264 1.187 
OA4 E10 0.270 0.139  F10 0.085 *  #@ 
OA5 C10 0.101 *  D10 0.146 *   
OA6 A10 0.087 *  B10 0.109 *   
OA7 G11 0.074 *  H11 0.068 *   
OA8 E11 0.066 *  F11 0.061 *   
OA9 C11 0.080 *  D11 0.067 *   
OA11 A11 0.087 *  B11 0.086 *   
OA12 G12 0.056 *  H12 0.082 *   
OA16 E12 0.117 *  F12 0.062 *   
OA17 C12 0.085 *  D12 0.089 *   






Figure 4.6. Photograph of the MMP-13 ELISA Results on 04/15/04. The first 2 columns are 
consistent with a standard serial dilution.  The wells containing both sample and standard are 




The advantages of ELISA over other methods of enzyme detection and measurement include the 
ability to quantify the concentration of the enzyme in a sample, the results are available within a 
few hours, and specificity of the test kit is dictated by the specificity of the antibodies employed.  
However, the disadvantages include the inability to discriminate enzyme activity from total 
enzyme concentration, the need for antibodies and there is ample opportunity for operator error. 
 
The results listed above revealed at least three problems with using the ELISA kits: 1) 
inconsistent paired standards and samples, 2) poor recovery of the human standard when mixed 
with a canine sample, and 3) no TIMP-1 results. 
 
The inconsistency in optical density of the paired standards and of the samples is likely an 
indication of inconsistent washing of the wells or dispensing of the samples.  All dispensing and 
washing was performed by hand, as an automated plate loader and washer was not available. 
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On 08/08/03, some difficulty occurred in dispensing the samples because of the synovial fluid 
sample viscosity.  Hyaluronidase digestion of the samples was prolonged from 1 hour to 6 hours 
for the remainder of the ELISA assays.  Care was taken to dispense the samples accurately.  On 
08/08/03, the Pearson coefficient (R2) of the standard curve was 0.9882 indicating nearly 99% of 
the optical densities of the standards could be attributed to the appropriate serial dilutions and 
loading and washing of the first 2 columns of wells.  Because resultant optical densities of 
several of the paired samples were not within 10%, I assumed that operator error attributed to the 
inconsistencies.  However, in retrospect poor attachment of the canine MMPs to the primary 
antibody could have contributed to the inconsistency. 
 
On 04/14/05, the MMP-3 and MMP-13 ELISAs had poor standard curves and all of the wells in 
a particular column were either too dark or too light indicating poor washing of the wells.  The 
TIMP-1 ELISA, run later in the day, was unable to detect any canine TIMP-1 in the samples.  
However, the standard curve was appropriate.  Over-washing of the wells could have contributed 
to the lack of detection. 
 
Using the remainder of the samples from 04/15/05, the MMP-3 and MMP-13 ELISAs were 
again run, paying attention to washing the wells appropriately.  In addition to the samples from 
the day before, two concentrations of standard were combined with a sample.  In wells, A9 and 
B9 50μL of synovial fluid from sample AO3 and 50μL of 30ng/mL standard were loaded.  In 
wells G10 and H10 50μL of sample and 50μL of 120ng/mL standard were loaded.  Wells A9 and 
B9 should have had calculated end-point concentrations of at least 15ng/mL; wells G10 and H10 
at least 60ng/mL.  Well A9’s calculated concentration was just 8.242 ng/mL and well B9’s 
concentration was just 3.446 ng/mL, well below that expected.  Well G10’s calculated 
concentration was just 18.724 ng/mL and well H10’s concentration was just 14.81 ng/mL, well 
below that expected.  Below expected concentration was likely due to occupation of the well’s 
solid phase primary antibody by canine MMP without attachment of the conjugated detection 
antibody to the canine MMP.  The occupation of the well’s primary antibody by the canine MMP 
prevented attachment by and detection of the human standard.  If competition for the primary 
antibody attachment site had been consistent, the resultant detectable concentrations would have  
had a linear relation to the expected value.  From the detected concentrations, the actual 
concentrations in canine samples could have been calculated.  The recovery was not consistent, 
however.  Similar results were produced by the MMP-13 ELISA. 
 
The inability of the ELISA kit to detect MMP-3 was unexpected.  The test kit insert states cross-
reactivity to horses, indicating some cross-species reactivity.  Cross-reactivity to other species 
has not been substantiated.  Designing and using a canine specific FAb’ HP conjugate rather than 
the human FAb’ supplied would allow using the remainder of the test kit.  Since the supplied 
human MMP-3 FAb’ consists of only a single light chain and part of a heavy chain, it is likely 
the antibody is limited in the antigens to which it can attach.  Because two monoclonal 
antibodies are used in the MMP-13 test kit, it is likely that the MMP-13 test kit suffers from the 
same inability to attach to canine MMP-13. 
 
The package insert of the TIMP-1 ELISA kit has been changed recently to indicate that there is 
no cross-reactivity to other species.  It is possible that canine TIMP-1 does not attach to the 
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primary antibody or that the conjugated detection antibody in the TIMP-1 ELISA kit does not 
attach to the canine TIMP-1 molecule. 
 
The ELISA test kits were not able to reliably measure canine enzymes and were abandoned.  
Because antibodies designed specifically to detect canine MMPs were not available, methods of 
indirectly identifying MMPs were investigated. 
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Sodium dodecyl (lauryl) sulfate polyacrylamide gel electrophoresis, SDS-PAGE, separates 
protein molecules by size (i.e. molecular weight).  Polyacrylamide gel is a cross-linked matrix 
that acts as a sieve to filter proteins.  Smaller protein molecules are able to travel through the gel 
mesh faster than larger molecules.  Proteins are first made linear by denaturing them in the 
anionic detergent SDS.  The proteins lose their secondary, tertiary and quaternary structure 
becoming linear and uniform in charge, allowing them to be separated on solely size.  The 
proteins are added to the negative end of the gel.  An electric current is applied across the 
polyacrylamide gel.  The proteins, having a negative charge, travel across the gel toward the 
positive pole.  The gel and the traveling proteins are stained.  Standards of known molecular size 
are used for comparison. 
 
In zymography, the polyacrylamide gel contains a protein substrate (i.e. casein or gelatin).  After 
the proteins are electrophoresed across the gel, they are renatured.  The proteins are incubated 
allowing digestion of the gel.  Then the proteins, both substrate and sample, are stained.  A 
clearing in the gel indicates a site of substrate digestion.  Casein is a substrate for a limited 
number of enzymes, including, MMP-1, -3, -7, -9, -10, -11, -12, -13, -28, plasmin and caseinase.  
Casein digestion has been used to support the presence of MMPs.1-3  Inhibition by 
ethylenediamine tetra-acetic acid (EDTA) has been used to support the identification of MMPs.2-
4  EDTA is a chelator of divalent cations.  Because MMPs require calcium for activation and 
contain zinc at their active site, the addition of 20mM EDTA inhibits MMP activation and 
activity.  By the addition of 1mM phenylmethylsulphonyl fluoride (PMSF), inhibition of serine 
proteases, like plasmin, can be used to differentiate MMPs.5 
 
Human MMP-3 is secreted as 57 and 59 kDa precursor forms.  The active form is 45 kDa in size.  
Autolysis to a 28 kDa and other forms occurs.6 Human MMP-13 is secreted as a 60 kDa 
precursor form.  The active form is 48 kDa in size.7 Human TIMP-1 has a molecular weight of 
28.5 kDa.8  Plasminogen weighing 92 kDa is the zymogen form of plasmin at 83 kDa.  Caseinase 






A 50 mg/mL casein solution in 1.5 M Tris with a pH of 8.8 was made.  The components were 
allowed to dissolve slowly. Then they were centrifuged to pellet the insoluble material. The 
supernatant was stored at 4°C.  A 4X loading buffer was made by combining 2.8 mL ddH2O, 1 
mL 0.5 mL Tris-HCl (pH 6.8), 0.8 mL glycerol, 3.2 mL 10% SDS, and 0.2 mL 0.2% 
bromophenol blue.  For each 12% SDS-PAGE resolving minigels with gelatin the following 
were combined: 1.25 mL ddH2O, 1.00 mL Tris (pH 8.8), 200 μL casein solution, 50 μL 10% 
SDS, 2.0 mL 30% acrylamide/bis, 4 μL N, N, N', N' tetramethylethylene-diamine (TEMED), and 
25 μL ammonium persulfate solution (0.1g/mL). For each 5% SDS-PAGE stacking minigels the 
0.33 mL 30% acrylamide/bis, 1.00 mL ddH20, 0.5 mL 0.5 Tris (pH 6.8), 20 μL 10% SDS, 10 μL 
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ammonium persulfate solution (0.1g/mL), and 5 μL TEMED were combined.  To create a 5X 
running buffer, 125 mM Tris-HCl (pH 8.3), 1.23 M glycine, and 0.5% SDS were combined.  A 
10X incubation buffer was made by combining 6.05g Tris base, 31.5g Tris-HCl, 58.5g NaCl, 
3.7g CaCl2, and 1 mL Brij 35.  The 10X incubation buffer was diluted to 1:10 before using.  A 
staining solution was made by combining 0.25% Coomassie Blue R250, 40% methanol and 10% 
acetic acid.  A destaining solution was made by combining 40% methanol and 10% acetic acid. 
A lysis buffer was made by combining 10 mM Tris, pH 7.4, 20 mL of 100mM Tris, pH 8.8, 
1.75g 150 mM NaCl, 2mL 1% triton x-100, and 1 mL 0.5% NP40.  The pH was adjusted to 7.4.  
The following reagents were also required: 1.5 M Tris-HCl with a pH of 8.8, 0.5 M Tris-HCl 
with a pH of 6.8, and 2.5% Triton X-100. 
 
Casting the Gel 
 
A discontinuous system was used by producing a 12% polyacrylamide resolving gel and using a 
5% stacking gel.  The glass gel plates were cleaned with 95% ethanol.  The plates were 
assembled by placing them in a casting stand.  The resolving gel solution components were 
mixed, except for the TEMED and APS.  Just prior to cast the gel, the APS and TEMED were 
added.  The solution was mixed well.  Using a pipette, about 3.75 mL of the solution was added 
to each sandwich.  A layer of ddH20 was added over the gel solution and the gel was allowed to 
polymerizing at least 20 minutes.  The combs were cleaned with 95% ethanol and allowed to dry.  
The components of the stacking gel were mixed, except for the TEMED and the APS.  When the 
resolving gel had polymerized, the water layer was decanted and the residual liquid wicked 
away. The combs were inserted part way, leaving room to cast the stacking gel. The stacking gel 
was cast using a transfer pipette, filling the sandwich to the very top.  The combs were 
completely inserted, dislodging any bubbles. Some of the stacking gel solution was allowed to 
overflow, reducing the number of trapped bubbles.  The stacking gel was allowed to polymerize 
at least 20 minutes. 
 
The samples were then prepared by mixing the sample with the loading buffer using a 1:4 ratio.  
The loading buffer used depended on the concentration of the sample, the amount of the sample 
loaded into each well and the volume capacity of the well.  A different concentration of loading 
buffer may be used to accommodate varying conditions.  The tube was mixed by flicking the 
tube with a finger then briefly centrifuged so that all of the mixed sample was in the bottom of 
the tube. 
 
Running the Gel 
 
The gel was run by assembling the gel onto the electrode/gasket section of the gel apparatus and 
inserting the entire apparatus into the buffer tank.  The running buffer was diluted to 1X.  The 
running buffer was added to the bottom of the tank until it reached 1-2 cm above the bottom of 
the glass plates.  The comb was gently removed.  Running buffer was added to the central well 
until it reached the top of the larger outside glass plate.  The wells were rinsed using a transfer 
pipette or needle and syringe.  The wells were loaded with samples.  The electrodes were 
attached to the gel apparatus and the power supply.  The gel was electrophoresed at 90 volts at 
4°C until the bromophenol blue band ran off the bottom. 
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Staining and Destaining of the Gel 
 
The gel was disassembled.  The stacker gel was remove and discarded.  The gel was washed 
twice with gentle rocking for 15 minutes each in 2.5% Triton X-100.  The gels were incubated at 
37°C overnight in zymography incubation buffer.  The gel was stained for 2 hours at room 
temperature in Coomassie Blue solution.  The gels were destained in methanol/acetic acid until 




The MMP-3 standard is received as a latent zymogen.  Activation can be performed by 
incubation with trypsin or with 4-aminophenylmercuric acetate (APMA).  Trypsin activation was 
used for the zymograms.  The following reagents were needed for activation. An activation 
reaction buffer was made containing 50 mM Tris, 0.15 M NaCl, 5.0 mM CaCl2, and 0.05% Brij 
35.  A 40 µg/mL trypsin stock was created by adding 10 mL activation buffer to the 50 mg 
trypsin vial.  The combination was mixed to dissolution.  Fifty µl of this solution was added to 
6.2 mL of activation buffer to get a 40 µg/mL stock.  The stock solution was divided by taking 1 
mL and dividing it into 100 µL aliquots and the rest into 1 mL aliquots.  The aliquots were stored 
at -20°C.  Ten mM PMSF stock solution was made by dissolving 0.02 g of PMSF in 10 mL of 
100% ethanol.  The solution was divided into 1 mL aliquots and stored at -20°C.  The MMP-3 
standard was activated by adding 5 µl of 40 µg/mL trypsin stock to one 20µL aliquot of MMP-3 
to a 10 µg/mL final concentration.  The standard was incubated at 37°C for 30 minutes.  The 
reaction was stopped by adding 5 µL of 10 mM PMSF (2 mM final concentration). 
 
Zymogram 1 was run on 09/29/05 using sample OA4 synovial fluid.  Well 1 was loaded with 10 
μL of molecular weight markers (Full-Range Rainbow™ Molecular Weight Markers, RPN800, 
Amersham Biosciences).  Well 2 was loaded with 1 μL of activated MMP-3 standard (Human 
Matrix Metalloproteinase-3 Purified Protein, CC1035, Chemicon International, Inc.).  Wells 3-6 
were loaded with 16, 8, 4, and 2 μL of sample respectively.  Pre-digestion with hyaluronidase 
was not performed.  Wells 7-10 were loaded with 16, 8, 4, and 2 μL of sample respectively.  Pre-
digestion for 1.5 hours with hyaluronidase was performed.   
 
Zymogram 2 was run on 10/06/04 using sample OA15 synovial fluid and cartilage from N24.  
Well 1 was loaded with 10 μL of molecular weight markers.  Well 2 was loaded with 1 μL of 
activated MMP-3 standard.  Wells 3&4 were loaded with 8 & 4 μL of sample OA15 
respectively.   Wells 5&6 were loaded with 8 & 4 μL of sample OA15 respectively.  EDTA was 
also added to wells 5 & 6.     Pre-digestion for about 6 hours with hyaluronidase was performed.  
Wells 7-9 were loaded with 27, 16 & 8 μL of sample N24 respectively. 
 
Zymogram 3 was run on 10/06/04 using sample OA15 cartilage.  Well 1 was loaded with 10 μL 
of molecular weight markers.  Well 2 was loaded with 1 μL of activated MMP-3 standard.  Wells 
3, 4 & 5 were loaded with 27, 16 & 8 μL of sample respectively.  Wells 6, 7 & 8 were loaded 







Zymogram gels were digitally scanned (HP ScanJet 5470c, Hewlett-Packard Co., Palo Alto, CA) 
in True Color and at 1200x1200 dots per inch.  The images were then processed using 
commercially available software (Adobe Photoshop 7.0, Adobe Systems Incorporated, San Jose, 




The zymography produced heavy bands near 100 kDa and faint bands at 30 kDa.  The bands in 
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Figure 5.1. Zymogram 1 – OA4 Synovial Fluid.  Note the heavy dark band near the top of the 




Improvement is seen in zymogram 2, figure 5.2.  Multiple, heavy bands were present between 75 
and 105kDa.  Some wavy distortion remains.  In wells 3 and 5, a moderate band appears at 
45kDa.  That same band is seen at 35kDa in wells 4 and 6. Wells 4 and 6 contain less sample.  In 
addition, all four wells have a faint band at 30 kDa.  The wavy distortion is not seen in the wells 
containing cartilage extract.  Similar bands are seen in the synovial fluid and cartilage extract.  
The bands in the cartilage extract are faint.  In addition, there is a heavy single band weighing 
18kDa.   
 
In zymogram 3, figure 5.3, casein digestion is inhibited by the addition of EDTA.  There is a 














Figure 5.2. Zymogram 2 – OA15 Synovial Fluid (with and without EDTA) and N24 














Figure 5.3. Zymogram 3 – OA15 Cartilage (with and without EDTA).  Multiple clear bands 
are noted between 45 and 48 kDa and between 75 and 100 kDa.  The bands do not appear when 




The advantages of zymography include the ability to detect and measure active enzymes.  
Proforms of the enzyme or MMPs bound to TIMPs or other nonspecific inhibitors are not 
measured.  Semiquantitative analysis is possible using zymography.  Gels are scanned and stored 
digitally.  Commercial software, like the aforementioned Adobe Photoshop 7.0, can be used to 
measure the area of the casein digestion.  By comparing to the area of digestion from a standard 
of known concentration, the concentration in samples can be assessed.  The area of digestion 
may not be linearly related to the concentration of MMP.  However, general comparisons (less 
concentrated, similar concentrations and higher concentration) could be made. Standardization of 
the amount of cartilage or joint fluid added to each well would be necessary to allow comparison 
between samples. 
 
The disadvantages of zymography include the two day protocol and the inability to positively 
identify the enzyme detected.  The evidence of the existence of the enzyme, molecular weight 
and casein digestion, is circumstantial.  Positive identification would require amino acid 
sequencing, mass spectrometry, or attachment by a specific antibody. 
 
The smearing evident in the synovial fluid samples in Figures 5.1 and 5.2 is most likely due to 
hyaluronic acid breakdown products, entangled with MMPs, still present in the synovial fluid.  In 
Figure 5.2 note the improvement in the zymogram.  Longer digestion with hyaluronidase likely 
resulted in smaller breakdown products and less dragging through the gel matrix. 
 
In the zymograms of articular cartilage, the band at about 18kDa may be an active MMP 
breakdown product.  Autolysis produces active MMP-3 and MMP-13 breakdown products.  This 
band is not evident in the synovial fluid samples.  The concentration of active MMPs may be 
higher in the cartilage samples, therefore more autolytic breakdown product would be expected.  
Preparation of the cartilage samples by grinding may have caused autolysis to occur.  The casein 
digestion at 18kDa, however, is not inhibited by the addition of EDTA. 
 
A portion of bands present in the zymograms between 75 and 105 kDa may have been caused by 
plasmin.  Plasmin is increased in joints after trauma9 and in arthritis.10, 11  Plasmin may also play 
a role in MMP activation.12  Deactivation of plasmin with PMSF could be used to eliminate its 
role in casein digestion and aid in distinguishing its contribution from that of MMPs. 
 
The bands present at 45 – 50 kDa and the absence of the bands when EDTA is incubated with 
the samples, is supportive of the existence of MMP-3 and MMP-13 in the samples.  Additional 
zymograms of both synovial fluid and cartilage from normal and osteoarthritis dogs would be an 
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CHAPTER 6.  WESTERN BLOT 
 
WESTERN BLOTTING INTRODUCTION 
 
Enzyme-assisted immunoelectroblotting (Western Blotting or immunoblotting) is a semi-
quantitative method of identifying one protein from a mixture of proteins.  Proteins are separated 
by mass using SDS-PAGE.  The proteins are then electrophoretically transferred from the 
polyacrylamide gel to a nitrocellulose membrane.  The protein bands from the gel are imprinted 
onto the membrane.  Proteins are then separated by antigenicity by detection during the 
immunoassay step.  The membrane is flooded or blocked with a concentrated protein solution 
(i.e. 10% fetal calf serum, BSA or 5% non-fat milk powder) preventing non-specific binding of 
proteins (i.e. detection antibody) to the membrane.  The first antibody is added.  This antibody 
recognizes and attaches to the protein of interest.  A second, detection, antibody is added.  The 
second antibody is often directed at a species-specific site on the first antibody.  The second 
antibody is conjugated to a detection enzyme.  The detection enzyme’s substrate is added 




Synovial fluid samples were incubated for 24 hours at 37°C with hyaluronidase.  The samples 
were vortexed every 6 hours.  Just before centrifugation, the samples were forcefully drawn 
through an 18-gauge needle to homogenize the samples and destroy remaining cells.1, 2 Samples 
were then centrifuged at 4000g for 10 minutes.  The supernatant was used for assay. 
 
Standard 14% SDS-PAGE gels were produced as described by Laemmli.3  The gels were 
electrophoresed at 150 volts for about 80 minutes at 25°C. 
 
Freshly-electrophoresed SDS-PAGE gels were dipped in cold 4°C transfer buffer for 25 minutes.  
Proteins were transferred/electrophoresed onto nitrocellulose membrane (nitrocellulose 0.45 um, 
162-0145, Bio-Rad Laboratories, Hercules, CA) using 90 volts for 90 minutes.  The membrane 
was blocked with dilute fat-free milk proteins at 4°C for 19 hours (overnight).  The membrane 
was washed 4 times for 15 minutes in wash buffer.  The first antibody (goat polyclonal anti-
human MMP-3, AF513, R&D Systems Inc, Minneapolis, MN or goat polyclonal anti-human 
MMP-13, AF511, R&D Systems Inc, Minneapolis, MN) was incubated with the nitrocellulose 
membrane for 60 minutes.  MMP-3 was used for blots 1-5; MMP-13 for blot 6.  The membrane 
was washed for 60 minutes.  The secondary anti-goat antibody horseradish peroxidase conjugate 
(Anti-goat IgG-HRP Antibody, HAF109, R&D Systems Inc) was incubated with the membrane 
for 60 minutes.  The membrane was washed for 60 minutes.  The membrane was incubated with 
light-emitting substrate (ECL™ Western Blotting Detection Reagents, RPN-2109, Amersham 
Biosciences) for 5 minutes at 25°C.  The blot was transferred to a radiographic cassette 
(Hypercassette, RPN 13649, Amersham Biosciences) containing radiographic film designed for 
Western blotting (Hyperfilm™ ECL™, RPN-2114K, Amersham Biosciences). 
 
For Western blot 1 on 03/16/05, synovial fluid samples OA27-30 were used.  Well 1 was loaded 
with 5 μL of molecular weight markers (Full-Range Rainbow™ Molecular Weight Markers, 
RPN800, Amersham Biosciences).  Well 2 was loaded with 1 μL of un-activated MMP-3 
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positive control (Human Matrix Metalloproteinase-3 Purified Protein, CC1035, Chemicon 
International, Inc.), 4 μL PBS and 5 μL loading dye.  Wells 3-6 were loaded with 5 μL loading 
buffer and 5 μL of 1:100 loading buffer diluted samples OA27-30 respectively.  Wells 8-11 were 
loaded with and 5 μL loading buffer and 5 μL of 1:50 diluted samples OA27-30 respectively.  
Wells 7, 12, 13, 14, & 15 were left unfilled. 
 
For Western blot 2 on 03/16/05, synovial fluid samples OA27-30 were used.  Well 2 was loaded 
with 1 μL of un-activated MMP-3 positive control, 4 μL PBS and 5 μL loading dye.  The divider 
between wells 1 and 2 was torn.  Well 7 was then loaded with MMP-3 positive control.  Samples 
were not diluted.  Wells 3-6 were loaded with 5 μL loading buffer and 5 μL of undiluted samples 
OA27-30 respectively.  Well 8 was loaded with 5 μL of molecular weight markers.  Wells 9-15 
were left unfilled.   
 
For Western blot 3 on 04/04/05, synovial fluid samples OA27-30 were used.  Wells 1 and 12 
were loaded with 5 μL of molecular weight markers.  Wells 2 and 7 were loaded with 1 μL of 
un-activated MMP-3 positive control, 4 μL PBS and 5 μL loading dye.  Wells 3-6 were loaded 
with and 5 μL loading buffer and 5 μL of 1:100 diluted samples OA27-30 respectively. Wells 8-
11 were loaded with 5 μL loading buffer and 5 μL of 1:200 diluted samples OA27-30 
respectively. 
 
For Western blot 4 on 04/04/05, synovial fluid samples OA27-30 were used.  Wells 1 and 12 
were loaded with 5 μL of molecular weight markers.  Wells 2 and 7 were loaded with 1 μL of 
un-activated MMP-3 positive control, 4 μL PBS and 5 μL loading dye.  Wells 3-6 were loaded 
with 5 μL loading buffer and 5 μL of 1:500 diluted samples OA27-30 respectively. Wells 8-11 
were loaded with 5 μL loading buffer and 5 μL of 1:1000 diluted samples OA27-30 respectively. 
 
For Western blot 5 on 04/26/05, cartilage samples OA8, OA14, N14, N20 and N21 were used.  
Well 1 was loaded with 5 μL of molecular weight markers.  Well 2 was loaded with 1 μL of un-
activated MMP-3 positive control, 4 μL PBS and 5 μL loading dye.  Wells 3-7 were loaded with 
and 5 μL loading buffer and 5 μL of 1:100 diluted sample. Wells 8-11 were unused.  The blot 
was exposed for 1 hour. 
 
For Western blot 6 on 05/03/05, cartilage samples OA8, OA14, N14, N20 and N21 were used.  
Well 1 was loaded with 5 μL of molecular weight markers.  Well 2 was loaded with 1 μL of un-
activated MMP-13 positive control (Human Matrix Metalloproteinase-13 Purified Protein, 
CC068, Chemicon International, Inc.), 4 μL PBS and 5 μL loading dye.  Wells 3-7 were loaded 
with and 5 μL loading buffer and 5 μL of 1:100 diluted sample. Wells 8-11 were unused.  The 




Figures 6.1 – 6.6 show the Western blot results.  In Western blots 1 and 2, note the bands at the 
interface between the loading and resolving gels.  The purified human standard migrated to the 






Figure 6.1.  Western Blot 1 - OA27-30 Synovial Fluid 1:50 & 1:100 Dilutions.  Note the 
bands at the junction of the loading gel and the resolving gel.  A band is also present between 50 






Figure 6.2.  Western Blot 2 - OA27-30 Undiluted Synovial Fluid.  Note the bands at the 







Figure 6.3.  Western Blot 3 - OA27-30 Synovial Fluid 1:100 & 1:200 Dilutions.  Note the 





Figure 6.4.  Western Blot 4 - OA27-30 Synovial Fluid 1:500 & 1:1000 Dilutions.  Dilutions 
of samples N27, N28, N29 and N30.  Note the absence of bands below the interface of the 














Figure 6.5.  Western Blot 5 - OA8, OA14, N14, N20 and N21 Cartilage Samples.  Note the 





Figure 6.6.  Western Blot 6 - OA8, OA14, N14, N20 and N21 Cartilage Samples probed for 







Western blot 6, using crude extract of cartilage samples and an antibody versus MMP-13, 




Western blotting has the advantage of providing more than one piece of evidence, molecular 
weight and antibody attachment, of the existence of a particular protein.  Western blotting can be 
semiquantitative by allowing the comparison the intensity or volume of bands to determine 
relative concentrations in samples.  Standardizing the volumes and weights of the samples used 
is necessary to make comparisons between samples.  Disadvantages include the two day protocol 
and the need for an antibody.  The specificity and sensitivity of the assay is determined by the 
antibody.  Human and canine MMP-3 and MMP-13 are highly homologous. By using a human 
polyclonal antibody, we were hoping at least one canine MMP epitope could be identified by the 
antibody. 
 
The presence of the bands at an unexpectedly high molecular weight can be interpreted as either: 
1) the antibody attached to a protein other than the MMP of interest or 2) the MMP did not 
migrate through the gel to the expected molecular weight.  Because we are using polyclonal 
antibodies to MMP-3 and MMP-13 and because many MMPs contain similar epitopes4, 5, it is 
possible the antibody attached to a different MMP or an unrelated protein (i.e. a protein with 
fibronectin-like amino acid sequences).  Failure of the samples to migrate to the expected 
molecular weight may be due to the presence of a protein covalently bound to the MMP making 
the enzyme a much higher molecular weight than expected.  The molecule attached to the MMP 
would have to be covalently bonded, since the Western blotting process breaks all non-covalent 
bonds.  The binding of TIMPs to MMPs is not covalent, this cannot account for the finding.  A 
high molecular weight pro-form of the MMP may exist in the samples.  By activating the 
proMMPs by the addition and incubation of the samples with trypsin or with 4-
aminophenylmercuric acetate (APMA), the contribution of proMMPs to the high molecular 
weight bands could be determined.  Canine MMP-3 and MMP-13 having a high molecular 
weight, much greater than that identified for human MMPs, could also account for the results.   
 
The possibility that canine MMPs have the expected molecular weight, but are not traveling 
through the gel appropriately must also be considered.  However, the proteins in the cartilage 
samples proved very reliable in traveling through the zymography gels; gels very similar to those 
used in the Western blots.  In gel 1, a very faint band did migrate to between 50 and 75 kDa in 
the OA28 sample well.  Believing that the failure of migration of the samples, in Western Blots 1 
and 2, was due to excessive protein in the sample, dilutions of the samples were attempted in 
Western blots 3 and 4.  Further dilution of the sample did not resolve the problem.   
 
Immunoprecipitation could be used to purify the samples before running them through the 
Western blots.  If other proteins within the sample milieu were interfering with the results, the 
additional step may prove useful.  Immunoprecipitation is a technique for removing a protein(s) 
from a milieu.  An antibody is added to a sample that binds the protein of interest.  The antibody-
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antigen complex is absorbed from solution through the addition of an immobilized antibody 
binding protein such as Protein A-Sepharose beads.  The sample is centrifuged, the resultant 
pellet contains only the proteins of interest.  The pellets are boiled to release the antibody-antigen 
complexes.  The sample is again centrifuged, the supernatant contains the protein of interest.  In 
this project, immunoprecipitation may have aided in freeing MMPs from the large amount of 
protein in the cartilage and joint fluid samples.  However, finding an antibody is problematic.  
Complete return of the enzyme to its tertiary and quaternary is not expected with this technique.  
Enzyme activity may, therefore, be affected. 
 
Rather than using a human polyclonal antibody, ideally, an antibody specifically designed to 
identify canine MMP-3 or MMP-13 would be made.  The antibody is often obtained by 
immunizing an animal with the protein of interest.   The foreign protein causes the injected 
animal to make antibodies specifically to that protein.  The antibody then must be verified to 
assure sensitivity and specificity.  Development of antibodies is well outside the scope of this 
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CHAPTER 7 - SUMMARY AND CONCLUSIONS 
 
CAUSE AND EFFECT 
 
The roles of MMPs in OA have not been fully elucidated.  However, there is significant 
circumstantial evidence of their roles in articular cartilage matrix destruction.  Ideal treatment for 
OA halts the mechanical and enzymatic degradation and breakdown of articular cartilage 
components.1  Assuming that the degree of enzymatic degradation of cartilage correlates with the 
concentration of active MMPs in cartilage, the assessment of treatment efficacy relies on the 
ability to measure the activity of degradative enzymes.   
 
The MMPs have important roles in normal every-day matrix remodeling.  The question arises as 
to whether increased MMP concentrations are a beneficial reaction to mechanical cartilage 
destruction or that the cartilage destruction is actually a result of excessive or unregulated 
MMPs.  The use of MMP concentrations as a measure of joint metabolism (i.e. cartilage 
destruction) does not require knowing the cause of the MMP concentration changes.  However, 
when designing a treatment for OA, knowing the cause versus the effect is required. 
 
VIABILITY OF TREATMENT STRATEGIES 
 
The treatment of OA through the inhibition of MMPs should cause one to be concerned.  The 
treatment of inflammatory conditions with non-steroidal anti-inflammatory drugs (NSAIDs) can 
lead to gastric ulceration and perforation, renal failure and bleeding disorders.  Through the 
inhibition of prostaglandin synthesis and subsequent reduction in inflammation, NSAIDs reduce 
pain.  However, selective inhibition of physiologic versus pathologically-induced prostaglandin 
synthesis is not currently possible.  When prostaglandin synthesis is inhibited, the need for 
prostaglandins by normal tissues, leads to pathologies in those normal tissues.  Though MMPs 
participate in cartilage destruction, the side effects of systemically inhibiting MMPs could be 
disastrous.  Because of the vital roles of MMPs in wound healing, bone and cartilage remodeling, 
and apoptosis, systemic inhibition may lead to unhealthy conditions worse than the disease being 
treated. 
 
CONTINUATION OF THIS PROJECT 
 
The vast majority of previous studies have measured the presence of MMPs disregarding the 
activity of the enzyme.  Because MMPs are highly regulated, measurement of the active enzyme 
would be more appropriate.  A solid-phase assay to measure human MMP-1, MMP-3, MMP-13, 
and MMP-14 has been recently developed.2  A solid-phase assay relies on a capture antibody 
attached to a 96-well plate.  The capture antibody must bind the MMP selectively without 
inhibiting catalytic activity.  A fluorogenic substrate is then added. The captured, active enzyme 
causes a detectable change in the substrate.  The antibodies utilized included a polyclonal 
antibody raised against the human MMP-3 linker region and a non-inhibitory monoclonal 
antibody raised against human MMP-13.  The homology of those specific locations on the 
correlate canine MMPs may allow the use of this assay in dogs. 
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A total collagenase activity assay kit was recently developed (ECM710, Chemicom 
International) to measure the combined activity of MMP-1, MMP-8 and MMP-13 enzymes.  The 
assay, because it relies on enzyme activity, not antibodies, may prove to be useful in veterinary 
medicine.   
The need for canine-specific MMP-3, MMP-13, and TIMP-1 antibodies in the continuation of 
this project is obvious.  Because of both monetary and time constraints, the development of anti-
canine antibodies was not possible as part of this study.  However, the potential market for such 
antibodies should make their development cost-effective.  There are several other human, mouse 
and rat polyclonal and monoclonal antibodies available on the market.  Their sensitivity and 
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APPENDIX: HUMAN AND CANINE MMP HOMOLOGY 
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1201 gaaaatcgat gcagccattt ctgataagga aaagaacaaa acatatttct ttgtagagga caaatactgg agatttgatg agaagagaaa ttccatggag 
     ......t... .....tg... t......... g.....g... ..g..c.... .c.....a.. .......... c......... ........c. a......... 
1301 ccaggctttc ccaagcaaat agctgaagac tttccaggga ttgactcaaa gattgatgct gtttttgaag aatttgggtt cttttatttc tttactggat 
     .......... .......... ...a...... .........g .......g.. .g........ .cg.....g. c......... t.ac..c... ..c.a..... 
1401 cttcacagtt ggagtttgac ccaaatgcaa agaaagtgac acacactttg aagagtaaca gctggcttaa ttgttgaaag agatatgtag aaggcacaat 
     .......... .......... .......... .......... ...tgt.... .....c.... .......... ....... 
1501 atgggcactt taaatgaagc taataattct tcacctaagt ctctgtgaat tgaaatgttc gttttctcct gcctgtgctg tgactcgagt cacactcaag 
 
 
Figure A.1: MMP-3 mRNA Homology - A comparison of Human gingival fibroblast mRNA (National Center for Biotechnical 
Information, http://www.ncbi.nlm.nih.gov/, accession number X05232) and Canine sarcoma mRNA (National Center for Biotechnical 
Information, http://www.ncbi.nlm.nih.gov/, accession number AY183143).  Human mRNA is in black •. A dot (.) indicates that the  
Canine nucleotide is identical to the Human sequence.  Canine mRNA substitutions are highlited •.  Total number of nuleotides 
compared is 1434.  There are 13 canine mRNA insertions and 219 substitutions.  There is an 85% homology. 
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   1 MKSLPILLLL CVAVCSAYPL DGAARGEDTS MNLVQKYLEN YYDLKKDVKQ FVRRKDSGPV VKKIREMQKF LGLEVTGKLD SDTLEVMRKP RCGVPDVGHF 
     .QN..A...F .GV......V .R..ED.NNN .E.T.Q.... ..N.G....P .....N.... .E........ ........V. ....AM..R. ........D. 
 
 101 RTFPGIPKWR KTHLTYRIVN YTPDLPKDAV DSAVEKALKV WEEVTPLTFS RLYEGEADIM ISFAVREHGD FYPFDGPGNV LAHAYAPGPG INGDAHFDDD 
     T....M.... ........M. ......R... ...I...... .K........ .TD......K ......D... .N........ .G...P.... .Y........ 
 
 201 EQWTKDTTGT NLFLVAAHEI GHSLGLFHSA NTEALMYPLY HSLTDLTRFR LSQDDINGIQ SLYGPPPDSP ETPL VPTEP VPPEPGTPAN CCDPALSFDA 
     ....S..S.. .........L .......... DPS.....V. NV....A..H .....V.... ....G..SDS SNDP.....S ...G.....A ._..T.....  
 
 301 VSTLRGEILI FKDRHFWRKS LRKLEPELHL ISSFWPSLPS GVDAAYEVTS KDLVFIFKGN QFWAIRGNEV RAGYPRGIHT LGFPPTVRKI DAAISDKEKN 
     I......F.F .......... ..T...GFY. .......... .L.....E.. ..I....... ....M..T.. Q....K.... .......K.. ...VF....K 
 
 401 KTYFFVEDKY WRFDEKRNSM EPGFPKQIAE DFPGIDSKID AVFEEFGFFY FFTGSSQLEF DPNAKKVTHT LKSNSWLNC 
     ......G... .......Q.. .......... ....V...V. .A..A...Y. ..N....... .........V ......... 
 
  
Figure A.2: MMP-3 Amino Acid Sequence Homology - A comparison of the translation of Human gingival fibroblast mRNA 
(National Center for Biotechnical Information, http://www.ncbi.nlm.nih.gov/, accession number X05232) and Canine sarcoma mRNA 
(National Center for Biotechnical Information, http://www.ncbi.nlm.nih.gov/, accession number AY183143).  Human amino acids are 
in black •. A dot (.) indicates that the  Canine amino acid is identical to the Human sequence. Canine amino acid substitutions are 
highlited •.  Total number of amino acids compared is 478.  There is 1 Canine deletion, 1 insertion and 91 substitutions.  There is an 





















   1 atgcatccag gggtcctggc tgccttcctc ttcttgagct ggactcattg tcgggccctg ccccttccca gtggtggtga tgaagatgat ttgtctgagg 
                            ......... .......... .......g.. ct..t..... .......... .c.a...... .___...... c......... 
 101 aagacctcca gtttgcagag cgctacctga gatcatacta ccatcctaca aatctcgcgg gaatcctgaa ggagaatgca gcaagctcca tgactgagag 
     .....t.... .c........ .......... a...c..... .t....cctg ....ct..t. .......... .a..tc.... ...g....ag ..g....c.. 
 201 gctccgagaa atgcagtctt tcttcggctt agaggtgact ggcaaacttg acgataacac cttagatgtc atgaaaaagc caagatgcgg ggttcctgat 
     ...t...... ........c. .......... ......c... .......... .t.....t.. ...g..ca.. .....g..a. .......t.. ...c...... 
 301 gtgggtgaat acaatgtttt ccctcgaact cttaaatggt ccaaaatgaa tttaacctac agaattgtga attacacccc tgatatgact cattctgaag 
     .....c..g. .......... ...c...... ..c..g.... ......c... cc........ ..g....... .c..t..... ....c..... .......... 
 401 tcgaaaaggc attcaaaaaa gccttcaaag tttggtccga tgtaactcct ctgaatttta ccagacttca cgatggcatt gctgacatca tgatctcttt 
     .t........ .......... ..t....... .......a.. ...g..a... .......... .......... t..c....c. ..a..t.... .......... 
 501 tggaattaag gagcatggcg acttctaccc atttgatggg ccctctggcc tgctggctca tgcttttcct cctgggccaa attatggagg agatgcccat 
     .....c...a ........g. .......t.. .........a ..t.....t. .t........ .......... .......... .......... .......... 
 601 tttgatgatg atgaaacctg gacaagtagt tccaaaggct acaacttgtt tcttgttgct gcgcatgagt tcggccactc cttaggtctt gaccactcca 
     .......... .......t.. .......... .......... .......... c.....c... ..c....... .......... .......... .......... 
 701 aggaccctgg agcactcatg tttcctatct acacctacac cggcaaaagc cactttatgc ttcctgatga cgatgtacaa gggatccagt ctctctatgg 
     .......g.. .......... .....c.... .......... g......... .......... ....c..... t.....g... .......... ..........   
 801 tccaggagat gaagacccca accctaaaca tccaaaaacg ccagacaaat gtgacccttc cttatccctt gatgccatta ccagtctccg aggagaaaca 
     c......... .......... ....c.g... ...c....ca .......... ....t..c.. .......... ........c. ....c..... ..........  
 901 atgatcttta aagacagatt cttctggcgc ctgcatcctc agcaggttga tgcggagctg tttttaacga aatcattttg gccagaactt cccaaccgta 
     .......... .......... .........a t......... .......g.. .......... ........a. ....c..... ...g...... .......... 
1001 ttgatgctgc atatgagcac ccttctcatg acctcatctt catcttcaga ggtagaaaat tttgggctct taatggttat gacattctgg aaggttatcc 
     .c........ .......... ..c..c.gc. ....t..... .......... ..c....... a......... .......... .......... .......... 
1101 caaaaaaata tctgaactgg gtcttccaaa agaagttaag aagataagtg cagctgttca ctttgaggat acaggcaaga ctctcctgtt ctcaggaaac 
     .c........ .......... .at....... ...g...... .......... .......... .........c ..g..g.... .g...t.c.. ...g......  
1201 caggtctgga gatatgatga tactaaccat attatggata aagactatcc gagactaata gaagaagact tcccaggaat tggtgataaa gtagatgctg 
     .......... .c........ .........g ..c....... .......c.. c..g..g... .....g.... .......g.. .......... ..g.....c. 
1301 tctatgagaa aaatggttat atctattttt tcaacggacc catacagttt gaatacagca tctggagtaa cc gtattgtt cgcgtcatgc cagcaaattc                   
     .......... ...c...... .......... ....t..g.. ...c...... ..g..t.ac. .......... ..c....... 
1401 cattttgtgg tgttaa 
  
 
Figure A.3: MMP-13 mRNA Homology - A comparison of Human mRNA (National Center for Biotechnical Information, 
http://www.ncbi.nlm.nih.gov/, accession number NM002427) and Canine fibrosarcoma mRNA (National Center for Biotechnical 
Information, http://www.ncbi.nlm.nih.gov/, accession number AF201729).  Human mRNA is in black •. A dot (.) indicates that the  
Canine nucleotide is identical to the Human sequence. Canine mRNA substitutions are highlited •.  Total number of nuleotides 










   1 MHPGVLAAFL FLSWTHCRAL PLPSGGDEDD LSEEDLQFAE RYLRSYYHPT NLAGILKENA ASSMTERLRE MQSFFGLEVT GKLDDNTLDV MKKPRCGVPD 
            ... .....Q.WS. ....D.._.. .....F.L.. ...K...Y.L .P.....KS. .G.VAD.... .......... .........I .......... 
 
 101 VGEYNVFPRT LKWSKMNLTY RIVNYTPDMT HSEVEKAFKK AFKVWSDVTP LNFTRLHDGI ADIMISFGIK EHGDFYPFDG PSGLLAHAFP PGPNYGGDAH 
     .......... .....T.... ........L. .......... .......... .........T ........T. .......... .......... .......... 
 
 201 FDDDETWTSS SKGYNLFLVA AHEFGHSLGL DHSKDPGALM FPIYTYTGKS HFMLPDDDVQ GIQSLYGPGD EDPNPKHPKT PDKCDPSLSL DAITSLRGET 
     .......... .......... .......... .......... .......... .......... .......... .......... .......... .......... 
 
 301 MIFKDRFFWR LHPQQVDAEL FLTKSFWPEL PNRIDAAYEH PSHDLIFIFR GRKFWALNGY DILEGYPKKI SELGLPKEVK KISAAVHFED TGKTLLFSGN 
     .......... .......... .......... .......... ..R....... ...Y...... .......Q.. ....F..... .......... .....F.... 
 
 401 QVWRYDDTNH IMDKDYPRLI EEDFPGIGDK VDAVYEKNGY IYFFNGPIQF EYSIWSNRIV RV MPANSILWC 
     ...S.....Q .......... .......... .......... .......... ..N....PYC 
  
  
Figure A.4: MMP-13 Amino Acid Sequence Homology - A comparison of the translation of Human mRNA (National Center for 
Biotechnical Information, http://www.ncbi.nlm.nih.gov/, accession number NM002427) and Canine fibrosarcoma mRNA (National 
Center for Biotechnical Information, http://www.ncbi.nlm.nih.gov/, accession number AF201729).  Human amino acids are in black •. 
A dot (.) indicates that the  Canine amino acid is identical to the Human sequence.  Canine amino acid substitutions are highlited •.  
Total number of amino acids compared is 453.  There is 1 canine deletion and 32 substitutions.  There is a 93% homology.  Post-






















     1 tcatcaggcc caagttcgtg gggacaccag aagtcaacca gaccacctta taccagcgtt atgagatcaa gatgaccaag atgtataaag ggttccaagc 
                                                                   ..... .......... .......... ....tc.... .t...agc.. 
 
   101 cttaggggat gccgctgaca tccggttcgt ctacaccccc gccatggaga gtgtctgcgg atacttccac aggtcccaca accgcagcga ggagtttctc 
       ...g...a.. ...t.g.... ....c..... .g........ ...c...... .c........ ......g... ........g. .......... .........g 
 
   201 attgctggaa aactgcagga tggactcttg cacatcacta cctgcagttt cgtggctccc tggaacagcc tgagcttagc tcagcgccgg ggcttcacca 
       g.c..c.... .c....g... c....a.... .......ac. .......... ......c..g .......... ....tacc.. .......... .......... 
 
   301 agacctacac tgttggctgt gaggaatgca cagtgtttcc ctgtttatcc atcccctgca aactgcagag tggcactcat tgcttgtgga cggaccagct 
       .......tg. ..c....... ....gg.... ........a. .....c.... .......... .......... ..a....... .......... ........           
 
   401 cctccaaggc tctgaaaagg gcttccagtc ccgtcacctt gcctgcctgc ctcgggagcc agggctgtgc acctggcagt ccctgcggtc ccagatagcc  
 
   501 tga 
  
  
 Figure A.5: TIMP-1 mRNA Homology - A comparison of Human placental mRNA (National Center for Biotechnical Information, 
http://www.ncbi.nlm.nih.gov/, accession number D11139) and Canine mRNA (National Center for Biotechnical Information, 
http://www.ncbi.nlm.nih.gov/, accession number AAS48102). Human mRNA is in black •. A dot (.) indicates that the  Canine 
nucleotide is identical to the Human sequence. Canine mRNA substitutions are highlited •.  Total number of nuleotides compared is 





   1 IRPKFVGTPE VNQTTLYQRY EIKMTKMYKG FQALGDAADI RFVYTPAMES VCGYFHRSHN RSEEFLIAGK LQDGLLHITT CSFVAPWNSL SLAQRRGFTK 
                        .. .......F.. .S...N.S.. ...D...L.. ....L...Q. ......V..N .R..H.Q.N. .......S.. .T........ 
 
 101 TYTVGCEECT VFPCLSIPCK LQSGTHCLWT DQLLQGSEKG FQSRHLACLP REPGLCTWQS LRSQIA 
     ..AA...G.. ..T.S..... ...D...... .. 
  
  
Figure A.6: TIMP-1 Amino Acid Sequence Homology - A comparison of the translation of Human placental mRNA (National 
Center for Biotechnical Information, http://www.ncbi.nlm.nih.gov/, accession number D11139) and Canine mRNA (National Center 
for Biotechnical Information, http://www.ncbi.nlm.nih.gov/, accession number AAS48102).  Human amino acids are in black •. A dot 
(.) indicates that the  Canine amino acid is identical to the Human sequence. Canine amino acid substitutions are highlited •.  Total 
number of amino acids compared is 114.  There are 22 canine substitutions.  There is an 81% homology.  Post-translational 
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